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A comprehensive summary of the work to be incorporated in the thesis entitled
“DESIGN AND SYNTHESIS OF HETEROCYCLES OF THERAPEUTIC
INTEREST” has been described as under.
[A] STUDIES ON PYRAZOLES
[B] STUDIES ON MICROWAVE INDUCED ORGANIC  REACTION
ENHANCEMENT
[A] STUDIES ON PYRAZOLES
The pyrazole ring is prominent structural motif found in numerous pharmaceutically
active compounds. Due to the rich pharmacological activity, pyrazole framework plays
an essential role in biologically active compounds and therefore represents an interesting
template for combinatorial as well as medicinal chemistry. Indeed pyrazole based
derivatives has shown several biological activities like antiinflammatory, antitumor,
antitubercular, amoebicidal,  anticonvulsant, hypnotic, CNS depressant, plant growth
regulatory activity and also used as herbicidal and fungicidal.
 These findings prompted us to design and synthesize some pyrazole derivatives
possessing better therapeutic values such as chalcones, pyrazolines, arylidines, pyrimidines,
cyanopyridines, cyanopyridones, isoxazoles, imidazolinones, acetonitriles and
arylaminomethyles. The study is described in the following parts.
PART-I :  STUDIES ON PYRAZOLINES
Pyrazolines constitute one of the most active class of compounds possessing
diversified biological applications such as anticancer, analgesic, antiinflammatory,
anticonvulsant, antimicrobial,  anthelmintic and antitubercular. Led by these
considerations, it was contemplated to synthesize some pyrazolines which have been
described in following sections.
SECTION - I : Synthesis and therapeutic evaluation of 1-Aryl-3-[1',N-phenyl- 3'-
   (2”,4”-dichlorophenyl)-pyrazol-4'-yl]-2-propen-1-ones
   2
The chalcone derivatives of type (I) have been prepared by the condensation
of 1,N-phenyl-3-(2’,4’dichlorophenyl)-4-formyl pyrazole with different aryl ketones
in the presence of 40% NaOH.
SECTION -II : Synthesis and therapeutic evaluation of 3-Aryl-5-[1',N-phenyl-
  3'- (2”,4”-dichlorophenyl)-pyrazol-4'-yl]-pyrazolines
The pyrazoline derivatives of type (II) have been prepared by the reaction of
chalcones of  type (I) with hydrazine hydrate in methanol.
SECTION -III : Synthesis and therapeutic evaluation of 1,N-Acetyl-3-aryl-5-[1',N-
     phenyl-3'-(2”,4”-dichlorophenyl)-pyrazol-4'-yl]-pyrazolines
N
N
R
O
ClCl
                                                          Type (I)                   R = Aryl
N
N
N N
R
Cl
Cl
H
                     Type (II)                   R = Aryl
N
N
N N
R
Cl
Cl
O
CH3
                                                          Type (III)                   R = Aryl
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The pyrazoline derivatives of type (III) have been prepared by the reaction of
chalcones of type (I) with hydrazine hydrate in glacial acetic acid.
PART-II :  STUDIES ON PYRIMIDINES
Pyrimidines derivatives are endowed with different therapeutic properties  such
as CNS depressant, in vitro activity against DNA and RNA viruses, antimalarial,
antibacterial and  antileukemic.
In view of these facts, it was thought worthwile to synthesize some new
pyrimidine derivatives bearing pyrazole nucleus which is described as under.
SECTION – I : Synthesis and therapeutic evaluation of 2-Arylimino-3,N-aryl-
     5-[1’,N-phenyl-3’-(2”,4”-dichlorophenyl)-4’-pyrazolylmethino]-
    4-Thiazolidinones
The arylidines of type (IV) have been prepared by condensation of 1,N-
phenyl-3-(2”,4”-dichlorophenyl)-4-formyl pyrazole with different thiazolidinones in
glacial acetic acid.
SECTION – II : Synthesis and  therapeutic evaluation of 6-Arylimino-7,N-aryl-
     2-oxo-4-[1’,N-phenyl-3’-(2”,4”-dichlorophenyl)- pyrazol-4’-yl]-
     1,2,3,4-  tetrahydrothiazolidino-[4,5-e]-pyrimidines.
            Type (IV)                  R = Aryl
N
N
N
S
NR
O
R
Cl
Cl
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Pyrimidinones of type (V) have been prepared by the condensation of 2-arylimino-
3,N-aryl-5-[1’,N-phenyl-3’-(2”,4”-dichlorophenyl)-4’-pyrazolylmethino]-4-
thiazolidinones with urea in glacial acetic acid with fused sodium acetate.
SECTION – III : Synthesis and therapeutic evaluation of 6-Arylimino-7,N-aryl-
        2-thio-4-[1’,N-phenyl-3’-(2”,4”-dichlorophenyl) pyrazol-4’-yl]-
                 1,2,3,4- tetrahydrothiazolidino-[4,5-e]-pyrimidines.
Pyrimidinones of type (VI) have been prepared by the condensation of 2-arylimino-
3,N-aryl-5-[1’,N-phenyl-3’-(2”,4”-dichlorophenyl)--4’-pyrazolylmethino]-4-
thiazolidinones with thiourea in glacial acetic acid with fused sodium acetate.
                                                          Type (V)           R = Aryl
                                                          Type (VI)                R = Aryl
HN
N
N
NH
S
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R R
Cl
Cl
HN
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S
N
N
S
R R
Cl
Cl
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PART-III :  STUDIES ON CYANOPYRIDINES
The emerging role of cyanopyridines in pharmaceutical chemistry stimulated
tremendous interest in the synthesis of cyanopyridines with therapeutic potential.
Cyanopyridine derivatives have been reported to be active as  antimicrobial, antimalarial,
antidiabetic and antihypertensive. Hence, it is pertinent  to synthesize some new
cyanopyridine derivatives possessing better therapeutic value which have been described
as under.
SECTION-I : Synthesis and therapeutic evaluation of 2-Methoxy-3-cyano-4- [1’,N-
 phenyl-3’-(2”,4”-dichlorophenyl)–pyrazol-4’-yl]-6-aryl-pyridines
2- Methoxy-3-cyanopyridines of type (VII) have been prepared by the
condensation of chalcones of type (I) with malononitrile and sodium methoxide.
SECTION–II : Synthesis and therapeutic evaluation of 2-Amino-3-cyano-4-
    [1’,N-phenyl-3’-(2”,4”-dichlorophenyl)–pyrazol-4’-yl]-6-aryl-pyridines
                                                          Type (VII)                 R = Aryl
                                                          Type (VIII)              R = Aryl
N
N
N
O
R
N
CH3
Cl
Cl
N
N
N
R
N
Cl
Cl
NH2
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2-Amino-3-cyanopyridines of type (VIII) have been prepared by the condensation
of chalcones of type (I) with malononitrile and ammonium acetate.
PART - IV : STUDIES ON CYANOPYRIDONES
Cyanopyridone derivatives play a vital role owing to their wide range of biological
activities such as anticancer, antibacterial, antiviral, anticonvulsant, insecticidal and antifungal.In
view of these facts, it was contemplated to synthesize cyanopyridone    derivatives which
have been described as under.
SECTION - I :  Synthesis and therapeutic evaluation of 3-Cyano-4-[1',N-phenyl-
    3'-(2”,4”-dichlorophenyl)-pyrazol-4'-yl]-6-aryl-1,2-dihydro-2-
   pyridones
The cyanopyridones of type (IX) have been prepared by the condensation of
chalcones of type (I) with ethylcyanoacetate and ammonium acetate.
PART - V : STUDIES ON ISOXAZOLES
It  has been reported that isoxazole derivatives possess remarkable
pharmacological importance and biological activities such as antifungal, antibacterial,
sedative and hypnotics.In order to develop medicinally important compounds, we have
synthesized some new isoxazole derivatives shown as under.
SECTION - I : Synthesis and therapeutic evaluation of 3-Aryl-5-[1',N-phenyl-
   3'- (2”,4”-dichlorophenyl)-pyrazol-4'-yl]-isoxazoles
                                                          Type (IX)                   R = Aryl
N
N
NH
O
R
N
Cl Cl
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The isoxazole derivatives of type (X) have been prepared by the reaction of
chalcones of type (I) with anhydrous sodium acetate and hydroxylamine hydrochloride
in glacial acetic acid.
PART - VI: STUDIES ON IMIDAZOLINONES
Imidazolinone derivatives have been found to be potent drug in pharmaceutical
and possess a wide range of biological activities such as anticonvulsant,
antiinflammatory, hypnotic, sedative, antihistamine and antithyroid. It appeared of interest
to design and synthesize imidazolinone derivatives, which have been described as under.
SECTION–I : Synthesis and therapeutic evaluation of 1,N-Aryl-2-phenyl-
  4-[1’,N-phenyl-3’-(2”,4”-dichlorophenyl)-4’-pyrazolylmethino]-
  imidazolin- 5-ones
                                                          Type (X)              R = Aryl
                                                           Type (XI)                 R = Aryl
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The imidazolinone derivatives of type (XI) have been prepared by the reaction
of azlactone with different aryl amines in pyridine.
PART-VII :  STUDIES ON ARYLAMINOMETHYL DERIVATIVES
Arylaminomethyl derivatives possess remarkable pharmacological importance and
biological activites,  such as antimicrobial, antimalarial, antibacterial. With a view to getting
better therapeutic agents and to evaluate it’s pharmacological profile, different type of
azomethine derivatives and  arylaminomethyl derivatives have been prepared, which have
been described as under.
SECTION - I :  Studies on N-Aryl-1,N-phenyl-3-(2’,4’-dichlorophenyl)-pyrazol-
    4-yl-azomethines
The azomethines of type (XII) have been prepared by the condensation of 1,N-
phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole with different aromatic amines.
SECTION–II : Synthesis and therapeutic evaluation of 4-Arylaminomethyl-
    1,N-phenyl-3-(2’,4’-dichlorophenyl) pyrazoles
                                                          Type (XII)                   R = Aryl
N
N
Cl
CH
N
R
Cl
N
N
Cl
CH2
NH
R
Cl
Type (XIII)                R = Aryl
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The compounds of type (XIII) have been prepared by the reaction of compounds
of type (XII) with an. NaBH4.
PART - VIII : STUDIES ON a-ARYLAMINONITRILES
The nitrile derivatives possess wide range of therapeutic activites such as  anti-
pyretic, analgesic, antiseptic, antimalarial, anithyroid, anticonvulsant and  antimicrobial
activities. In view of these facts, it appeared of interest to synthesize nitrile derivatives
which have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of a-Arylamino-[1’,N-
   phenyl-3’-(2”,4”-dichlorophenyl)-pyrazol-4’-yl]-acetonitriles
The nitriles of type (XIV) have been prepared by the condensation of
1,N-phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole with different aromatic amines
in  presence of sodium cyanide and glacial acetic acid at 0-5 0C.
[B] STUDIES ON MICROWAVE INDUCED ORGANIC  REACTION
ENHANCEMENT
Recently reported studies on the use of domestic microwave oven for thesynthesis
of heterocycles, showed that it is a safe, rapid and convenient methodology. Keeping in
view the substantial reduction in the reaction time with improved yield   under microwave
irradiation (MWI), it was thought worthwhile to synthesize acetyl pyrazolines and cyano
pyridines under MWI using a  microwave oven as well as in a conventional way.
N
N
NH
R
N
Cl
Cl
                                                          Type (XIV)                 R = Aryl
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PART - I : STUDIES ON ACETYLPYRAZOLINES
SECTION -I : Synthesis and therapeutic evaluation of 1,N-Acetyl-3-aryl-5-
   [1',N-phenyl-3'-(2”,4”-dichlorophenyl)-pyrazol-4'-yl]-pyrazolines
The pyrazoline derivatives of type (III) have been prepared by the reaction of
chalcones of type (I) with hydrazine hydrate in glacial acetic acid under microwave
irradiation in few minutes.
PART - II : STUDIES ON CYANOPYRIDINES
SECTION–I :Synthesis and therapeutic evaluation of 2-Methoxy-3-cyano-4[1’,N-
 phenyl-3’-(2”,4”-dichlorophenyl)–pyrazol-4’-yl]-6-aryl-pyridines
N
N
N NH3COC
R
Cl
Cl
                                                          Type (III)               R = Aryl
N
N
N
O
R
N
CH3
Cl
Cl
                                                          Type (VII)             R = Aryl
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CHARACTERISATION
The constitution of newly synthesised products have been supported by  using
elemental analyses, Infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
In vitro study on multiple biological activities
   (i) All the compounds have been evaluated for their antibacterial activity  towards
Gram positive  and Gram negative bacterial strains and antifungal activity towards
Aspergillus niger at a concentration of 40ìg. The biological activity of  the synthesised
compounds have been  compared with standard drugs.
   (ii) Selected compounds have been evaluated for their in vitro biological assay like
antitubercular activity towards a strain of Mycobacterium tuberculosis H37Rv at a
concentration of 6.25 ìg/ml using Rifampin as a standard drug,which have been tested
by Tuberculosis Antimicrobial Acquisition Coordinating Facility (TAACF),
Alabama,U.S.A.
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INTRODUCTION
The chemistry of the heterocyclic compounds is as logical as that of aliphatic or
aromatic compounds. This study is of great interest both from the theoretical as well as
practical stand point. A heterocyclic compound is one which possesses acyclic structure
with atleast two different kinds of atoms in the ring. The most common types, contain
largely carbon atom, nitrogen, oxygen and sulphur are the most common heteroatoms,
but many other elements, including even bromine, chlorine can also serve. The heterocycles
containing the less common atoms have been subject to much investigation in
recent years.
The variety of heterocyclic compounds is enormous, their chemistry is complex
and synthesizing them requires great skill. Among large number of heterocycles found
in nature nitrogen heterocycles are most abundant than those containing oxygen or
sulphur owing to their wide distribution in nucleic acid instance and involvement in almost
every physiological process of plants and animals.
Heterocyclic chemistry and medicinal chemistry share a venerable common history.
Many of the founders of heterocyclic systems had an intense interest not only in molecules
from nature but also in the effects of synthetic compounds on living systems.Heterocyclic
compounds have specific chemical reactivity and provides false sythons in biosynthetic
process or block the normal functioning of biological receptors. Modification of the
central heterocyclic ring then gave a series of drugs effective for the treatment of
depression- the tricyclic antidepressants. Benificial pharmacological property of
heterocycles has been test examplified by reduction of toxicity of sodium arsanilate in
trypanocide melarsprol (MELB) due to incorporation of arsenic atom in a heterocyclic
and subsequent substitution with s-triazine ring.
Communicable diseases account for approximately, one third of all the death in
the word according to the 1999 WHO report and new drugs and vaccines are urgently
needed both for prevention and treatment of infectious diseases. With the development
of a series of efficacious synthetic molecular modifiations that would  most likely lead to
biologically active mollecules, measures are taken to renew the efforts in the area of
infectious disease focusing on modern approaches including use of genomics is target
discovery and validation, combinatorial chemistry and highththroughput screening
methodology for lead discovery and structure based drug design.
The era which can be described as the era of actual discovery of new drugs
commencd after 1930. The concept of modern drug discovery was supported by Gerhard
Domagk.
A large number of important drugs have been introduced during the period of
1940 to 1960. This period is known as the ‘Golden period” of new drug discovery.
Thus starting from 1933, the first antibaterial drug ‘protonsil’ leading, and various
other sulpha drugs following, such as ; 1940-penicillin; 1945-chloroquine, antimalarial;
1950-methyldopa, antihypertensive; 1958-adrenergic beta blockers, coronary
vasodilatory; 1960-semi synthetic penicillin, antibacterial; 1967-disodium
chemoglycoate, antiallergic; 1972-cimetidine, H2-antagonist; 1975-verapamil, calcium
antagonist;1981-captopril, antihypertensive. These are some specific examples
representing new therapeutics.
The drug design is not completed without mentioning the serious efforts being
applied towards rational drug development. The rational design of an agent with specific
activity requires not only the targets that may be similar in many respects. Structure
based drug design is a general term for using protein structrural information from X-ray
crystallography and NMR spectroscopy to assist the design of novel therapeutic agents.
Approximately one third of the marketed drugs function primarily through direct
inhibition of enzyme activity. Thus new enzyme inhibitors have great potential to
become therapeutically useful in the cilnic and successful in the market.
In order to meet these challenges one needs to adopt novel approahes in
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pharmaceutical research. Both molecular biology and genetic engineering will be
exploited duly in opening up new routes.
It is earnestly believed that towards the begning of new century (2001 AD) keeping
in view the tremendous global technological competition, one is left with no other choice
than to intertionalize research and development of pharmaceutical drugs to achieve the
common objective “better drugs for a better word”.
AIMS AND OBJECTIVES
Taking in view of the applicability of heterocyclic compounds, we have
undertaken the synthesis of heterocycles bearing pyrazole nucleus. The placement of  a
wide variety of substituents of these nuclei have been designed in order to evaluate the
synthesised products for their pharmacological profile against several strains of bacteria
and fungi.
♦ To generate several derivatives like chalcones, pyrazolines, cyanopyridines,
isoxazoles, cyanopyridones, thiazolidinones, pyrimidines, imidazolinones,
arylaminomethyl, acetonitriles bearing pyrazole nucleus.
♦ To synthesise biologically active pyrazolines and methoxy pyridines using
microwave induced synthesis method.
♦ To check purity of all the compounds using thin layer chromatography.
♦ To characterise these products for stucture elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
♦ To evaluate new products for better drug potential against different strains
of bacteria, fungi and for antitubercular activity against Mycobacterium
Tuberculosis H37Rv.
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INTRODUCTION
Pyrazoles are heterocyclic compounds having a doubly unsaturated five-
membered ring containing two nitrogen atoms in adjacent positions.The name pyrazole
was given to such compounds, because the nucleus was derived from pyrrole by
replacement of carbon by nitrogen1.
Synthetic pyrazole derivatives contribute much to the searchable literature of
pyrazole derivatives,in huge libraries owing to their wide applicability in the field of
medicine,agriculture and industrial chemistry2-3.
Some  pyrazole derivatives are found in nature are Whitasomine(a), Pyrazofurin
or Pyrazomycin4(b), Formycin5(c) and b-Pyrazolylalanine6(d).
Whistasomine is an alkaloid isolated from the roots of an Indian medicinal
plant, Withania somnifera. Pyrazofurine is an antibiotic isolated from the fermentation broth
of Streptomyces candidus. Formycin is a naturally occuring isomer of adenosine
N
H
N
N N
C6H5
(a)
O
N
H
N
O
NH2OH
OH
OH
OH
(b)
O
OHOH
N NHOH
N N
NH2
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N
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L-β-pyrazolylalanine found in seeds of many species of Cucurbitaceae.
Pyrazole derivatives have been found to be active on CNS (Central Nervous system),
pharmcodynamic and chemotherapeutic agents, metabolic diseases and endocrine
functions7.
SYNTHETIC ASPECTS
Different methods for the preparation of pyrazoles have been cited in literature
are as below.
1. L. Knorr8 has synthesised two structrually isomeric pyrazoles by the condensation
of substituted hydrazines with 1,3-dicarbonyl compounds
2. H. V. Pechmann9 has synthesised pyrazoles by the reaction of acetylenes
and diazomethane.
3. P.T. Perumal and et.al.10 have synthesised pyrazoles by the reaction of
hydrazones with Vilsmeier reagent.
4. By the microwave assisted cyclocondensation of hydrazine derivatives with
alkyl dihalides11.
O
R
O
R2
R1 + NH2 NH
Ar N
N
R1
R2
Ar
R
+
N
N
R2 R1
Ar
R
+ 2H2O
CH CH + CH2 N N
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C6H3(NO2)2
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70-80  C, 4h
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H5C6H2CO2C
C6H3(NO2)2
H5C6
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5. R. C. Boruah  et .  al .12 suggested one pot synthesis of pyrazoles from
β-formylenamides.
6. Marica Theiszova et.al.13 have synthesised pyrazoles by condensation of
2-ethoxymethylene-3-oxobutanenitrile and hydrazines.
THERAPEUTIC IMPORTANCE
The biological activities are mainly classified in to four different categories.
(a) CNS  acting agents
(b) Pharmacodynamic agents
(c) Agents acting on metabolic diseases and endocrine functions.
(d) Chemotherapeutic agents
(a) CNS  acting agents
1. Antidepressants14
2. Antipsychotics15,16
3. Anxiolytics17
4. Sedatives and hypnotics18,19
5. Anticonvulsant20
6. Analgesics21,22
7. Antiparkinson23,24
8. Anti-alzheimer25,26
(b) Pharmacodynamic agents
9. Antiarrthythmic, antianginals, vasodilators, antihypertensives27,28,29
X XNH
NH2
+ N
N
R R
K2CO3,H2O
MW
R=H, Me, Cl X=Cl, Br, I
NH2OH.HCl
N
N
R1
Ac
R2
KH2PO4
C C
NHAc
R1R2
OHC
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10. Diuretics30,31
11. Antithrombotics32,33
12. Anti-allergics34
13. Antihistaminics35
14. Antiemetics36
15. Respiratory system37
16. Urogenital system38
17. Psoriasis39
(c) Agents acting on metabilic diseases and endocrine functions
18. Anti-inflammatory40
19. Hypoglycemic41,42
20. Steroidal hormones43,44
21. Liver alcohol dehydrogenase inhibitors45
(d) Chemotherapeutic agents
22. Anticancer46,47
23. Immunosuppressants and immunostimulants48
24. Antiviral49
25. Antibacterial 50, 51
26. Antiparasitic52
27. Fungicidal53
Antidepressants
Tricyclic structure containing pyrazole moiety and pyrazoloquinolin-3-one have
been synthesised to evaluate their GABAA-benzodiazepine receptor affinities54.Some of
the pyrazolepyrimidines or pyrazolopyridines are currently under clinical develoment55.
Pyrazolepyrimidines(I) have been also studied for their antagonistic properties for the
corticotropin releasing factor (CFR-1) receptor whose activation is related to depression
and anxiety56.
In search of new class of neuroleptic drugs, pyrazolo[1,5-a]pyridine (II) have
been evaluated for presynaptic dopamine autoreceptor agonist activity57
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Antipsychotics
Pyrazolopiperidine(III) and a series of structural analogs have been identified as
novel and selective human D4 receptor antagonists58,59.
Analgesics
Some pyrazole derivatives lik pyrazoline-5-one(piperylone, benzpiperylone,
antipyrine, pyrimidone), pyrazolin-3,5-diones (phenylbutazone, kebuzone,
sulfinpyrazone, oxyphenbutazone) possess good analgesic activity.
Antialzheimer drugs
Recently, 1H-pyrazole-1-carboxamidines have been shown to be  competitive
inhibitors of all three isoforms, the most selective compound, 1H-pyrazole-N-(3-
aminomethylanilino)-1-carboxamidine, was 100-fold selective for neuronal NOS over
endothelial NOS60.
Cardiovascular drug
Since the discovery of Iosartan, the first orally active non peptide, several
pyrazole derivatives have been synthesised. Out of which azopyrazolo[5,1-a]imidazole
was most interesting61. The compound (IV), UR-7280, showed high potency in vitro
and in vivo has been selected for clinical evaluation as an hypertensive agent62.
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Drug molecules having pyrazole nucleus with good pharmacological activities are
listed below.
N
N N
N NH
N
R1
R3
R2
(IV)
N
N
N
N CH3
O
CH3
N
Zaleplon
[Sedative, Hypnotic]
N
N
N
O
CH3
CH3
CF3
[Diabetic agent]
N
N
CH3
H2NO2S
CF3
Celecoxib
[Antiinflammatory]
N
N
CH3
N
PNU-32945
[HIV-1 Reverse tran-
scriptase inhibitors]
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N
N
H
Stanozolol
(Insecticide)
Stevan W. Djuric and co-workers63 have identified a series of bis
(trifluoromethyl)pyrazoles (BTPs) as a novel inhibitor of cytokine production and
even inhibit IL-2 production with a 10-fold enhancement over cyclosporine in an ex
vivo assay.
Genin et.al 64 prepared pyrazole derivatives of type (V) as anti HIV-1 reverse
transcriptase inhibitors with enhanced activity versus the delavirdine-resistant p236L
mutant. Devid L. S. et.al.65 have repored pyrazoles as activators of the nitrile oxide
receptor and  guanglate cyclase agent. Jun Sun et.al.66 have studid pyrazole derivatives
of type(VI) used as antagonist for astrogen receptor -α. Carbau Romuald and co-workers67
have reported pyrazole derivatives useful as reverse transcriptase inhibitors for the
treatment of HIV infection.
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Jaques Dumas and co-workers68 have synthesised pyrazole derivatives as
rafkinase and angiogenesis inhibitor agent. Zhao Zhong and co-workers69 have documented
liguly potent factor Xa inhibitors with in vitro  anticoagulant activity of pyrazoles.Jeffrey
roppe et. al.70 have discovered novel heteroaryl azoles that are metabotropic glutamate
receptor antagonists with anxiolytic activity.
Zainaba D. et. al.71 have investigated 1-phenyl-3-toluyl-4-[ortho-1’-(N-ethyl-
2’-methylpropylamine)]phenylpyrazole as antifungal agent and showed that mycelial
growth and conidial germination of fungi were blocked by the compound.
Atkinson R.N. et.al.72 have synthesised pyrazoles  as sodium channel blocker.
Jin Li and co-workers73 have reported pyrazole derivatives  as  COX-2 inhibitors. This
novel COX-2 inhibitors also showed a good pharmacokinetic profile (pk), intravenous
and subcutaneous (sc) dosing and demonstrated excellent in vivo efficacy in a cannine
synovities model. Hyun-Ja Park et.al.74 have documented pyrazole derivatives as
cytotoxic agent, exhibiting very potent cytoxicity against XF 498 and HCT 15.
Recently, Gill and Martyn Frederickson and co-workers75 have identified pyrazole
as a novel p38 MAP kinase inhibitors. Antimalarial activity of 4-(5-trifluoromethyl-1H-
pyrazol-1-yl)-chloroquine analogues has been evaluated in vitro against a chloroquine
resistant Plasmodium falciparum clone by Antoniana U. Krettli et. al.76.
Alice M. R. Bernardino et.al.77 have synthesised pyrazole derivatives, their
leishmanicidal in vitro activities and cytotoxic effects were investigated.Bantwal
Shivarama Holla et.al.78 have documented pyrazole derivatives as antimicrobial agent.
J. Guy Breitenbucher et.al.79  have reported pyrazole derivatives of type (VII) as CCK1
receptor antagonist.Pyrazole derivatives(VIII)  with nanomolar activity in the biochemical
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assay are able to efficiently inhibit CDK2-mediated tumor cell proliferation have been
reported by Paolo Pevarello et. al.80
                                      .
The universal template approach to drug design forsees that pyrazoles can be
modified in such a way to achieve better therapeutic agents. We have synthesised chalones,
pyrimidinones, isoxazoles, a-arylaminonitriles, cyanopyridones, arylaminomethyl bearing
pyrazole nucleus. These study is described in the following parts.
[A] STUDIES ON PYRAZOLES
PART - I :  STUDIES ON PYRAZOLINES
PART - II :  STUDIES ON PYRIMIDINES
PART - III :  STUDIES ON CYANOPYRIDINES
PART - IV :  STUDIES ON CYANOPYRIDONES
PART - V :  STUDIES ON ISOXAZOLES
PART - VI :  STUDIES ON IMIDAZOLINONES
PART - VII :  STUDIES ON ARYLAMINOMETHYL DERIVATIVES
PART - VIII :  STUDIES ON  α-ARYLAMINONITRILES
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INTRODUCTION
Pyrazoline is a five membered heterocyclic system with two nitrogen atoms at
the positions-1 and -2. In 1967 Jacobe, reviewed the chemistry of pyrazolines, which
have been studied extensively for their biodynamic behavior81. Pyrazoline ring is
prominent structural motif found in numerous pharmaceutically active compounds.Due
to the rich pharmacological activity, pyrazoline framework plays an essential role in
biologically active compounds and therefore represents an interesting templet for
combinatorial as well as medicanal chemistry.
SYNTHETIC ASPECTS
Different methods for the preparation of 2-pyrazoline derivatives documented in
literature are as follows.
1. 2-Pyrazolines can be constructed by the cyclocondensation of chalcones with
hydrazine hydrate82.
2. Synthesis of 2-pyrazolines has been achieved with a coupling-isomerisation
sequence of halorene, propargyl alcohol and methyl hydrazine83.
N
H
N
R O
R1
+ NH2.NH2.H2O
N
H
NR
R1
R, R1 = Aryl
Ar - x+
OH
ph
CH
1. pd(pph3)2cl2, Cul
Et3N, THF
2. MeNHNH2
N N
H
Ar ph
CH3
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3. 2-Pyrazolines can be synthesised by the one pot reaction of α, β-unsaturated
ketone and hydrazindiium dithiocyanate84.
4. Dipolar cycloaddition of nitrilimines of dimethyl fumarate, fumaronitrile and the
N-aryl maleimides yielded the corresponding pyrazolines85.
5. Epoxidation of chalcones with epoxy ketones on reaction with hydrazine
hydrate and phenyl hydrazine to gives pyrazolines86.
6. 2-Pyrazoline can be prepared by the condensation of α, β-unsatured ketone and
thiosemicarbazide in the presence of basic alumina and K2CO387.
Furthermore, B. Gyassi et al.88 have investigated one pot synthesis of
somepyrazolines in dry media under microwave irradiation. S. Paul et. al.89 and Dandia
Anshu et. al.90 have also described the microwave assisted synthesis of 2-pyrazolines.
MECHANISM
The following mechanism seems to be operable for pyrazolines by the condensation
of chalcones with hydrazine hydrate91.
Nucleophillic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl
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O
+ [H3N-NH3]2+ 2SCN
N
N
S
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R
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system forms species (b), in which the negative charge is mainly accommodated by the
electronegative oxygen atom.
Proton transfer from the nitrogen to negative oxygen produces an intermediate
enol which simultaneously ketonises to ketoamine (c). Another intramolecular nucleophillic
attack by the primary amino group of ketoamine on its carbonyl carbon followed by
proton transfer from nitrogen to oxygen leadsto carbonyl amine (d). The later with a
hydroxy group and amino group on the same carbon lose water molecule to yield the
pyrazolines (e).
THERAPEUTIC IMPORTANCE
From the literature survey, it was revealed that 2-pyrazolines are better therapeutic
agents. Some of the activities are mentioned below.
1.   Cardiovascular92
2.   Insecticidal93
3.   Anticonvulsant94,95
4.   Antiallergic96
5.    Antiimplantation97
6.   Antidiabetic98
7.   Antitumor99
8.   Antiinflammatory100
9.   Analgesic101,102
10.  Antineoplastic103
11.  Antimicrobial104
12. Bactericidal105,106
13. Tranquilizer107
14. Hypoglycemic108
15. Fungicidal109
16.  Herbicidal110
17.  Diuretic111
Nugent Richard112 investigated pyrazolines bisphosphanate ester as novel
antiinflammatory and antiarthritic agents. Tuntawy Atif and coworkers113 have patented
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3-methyl-4'-(substituted phenylazo)-pyrazol-5-ones as antibacterial agent. F. Manna and
co-workers114 have  descr ibed  1-ace ty l -5- (2 ' -bromophenyl) -4 ,5-d ihydro-
3- (2 ' -hydroxyphenyl ) -1H-pyrazolines and its derivatives which acts as potent
antiinflammatory, analgesic and antipyretic agent.
Ekta Bansal and co-workers115 have synthesised 1-acetyl-5-substituted ary-3-
(β-aminonaphthyl)-2-pyrazolines and evaluated for their antiinflammatory and ulcerogenic
activities. Marina Godaliza and co-workers116 have prepared fused pyrazolines
derivatives of type(I) and evaluated for their cyatoxic activity in P-388, A-549 and HT-29
culture cells.
Furthermore, Tsuboi et. al.117 have synthesised some new (phenylcarbonyl)
pyrazoline (II) as an insecticides and at 40ppm concentration show 100% mortality of
spodopetra litura larve after seven days.
Guniz Kucukguzel et. al.118 have synthesized pyrazolines as an antimicrobial
and anticonvulsant agent.Malhotra V. et. al.119 have synthesized new pyrazolines as a
NN
O
CH3 O CH3
O
CH3
O
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O
O CH3
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NN R''R
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cardiovascular agent (III). Almstead J. et. al.120 have prepared pyrazolines as
vascularization agent, it increas erythropoietin and vascularization of tissue in a subject
in need. Ahn J. H. et. al.121 have synthesised cyanopyrazoline derivatives(IV) and
documented as dipeptidyl peptidase(DP)-IV inhibitors and antidiabitic agents. Berghot
M. A.et.al.122 have synthesised pyrazoline derivatives of diazepam and reported their
antimicrobial activity.
 In spodoptera frugiperda pesticide studies with Brassica oleracea, at 500 ppm
some of pyrazolyl pyrazolines exhibited 100% mortality after seven days and some of
compounds were claimed to be useful as pesticidal coating material agents123. Matysiak
J. et. al.124 have sythesised some novel pyrazoline derivatives which exhibited
comparable or higher activity than itraconazole and fluconazole tested under the same
experimental condition.
M. Dora et.al125 have synthesised pyrazoline derivatives as antiinflammatory
agents(V). Tae-Sook Jeong et. al.126 have reported pyrazole as low-density
lipoprotein (LDL) antioxidant activity in the TBARS assay. Joanna Matysiak and
Andrzej Neiwiadomy127 have described fungistatic activity of pyrazoline derivatives
of type (VI).
Nesrin Gokhan et. al.128 have synthesised new 1,N-substituted thiocarbomoyl-
N NH
NH
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N
N
CN
N
(IV)
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3-phenyl-5-thienyl-2-pyrazoline derivatives and evaluated  for antidepressant, antiogenic
and mammalianmonoamine oxidase (MAO)- A & B inhibitory activities.David  Jones and
co-workers129 have synthesised 4-substituted pyrazolines as PR antagonists(VII).F. Chimenti
et. al.130 have discovered series of N,1-substituted 3-5-diphenylpyrazolines  and
reported their antihelicobacter pyroli activity.
Recently, a series of new 1,N-substituted pyrazoline analogues (VIII) of
thiosemicarbazones were synthesised by Mohammad Abid and Amir Azam131 as
antiamoebic agent.Gulberk Ucar et.al132 have synthesised 1-N-substituted
thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines and reported them as a novel
cholinesterase and selective monoamine oxidase β inhibitors for the treatment of
Parkinson’s and Alzeimer’s disease.Y. Rajendra Prasad et. al.133 have synthesised some
1,3,5-triphenyl-2-pyrazolines and 3-(2’’-hydroxy naphthalen-1”-yl)-1,5-diphenyl-2-
pyrazolines  derivatives of type(IX) as antidepressant agent.
CONTRIBUTION FROM OUR LABORATORY
S. D. Sorthiya et. al.134 have synthesised and tested the antimicrobial activity of
N
N
OH
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R2 R3
R4
R1
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N
N S
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N
Cl
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CH3
CH3
(VII) (VIII)
(IX)     R1,R2,R3,R4 =Alkyl
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p-(2',5'-Dibromobenzenesulphonamido)-phenyl-5-aryl-1H/acetyl/phenyl-2-pyrazolines.
Parekh et. al.135 have prepared 1-acetyl-5-aryl-3-[3-(3,4-dihydro-2-methyl-4-one-
3-quinazolinyl)-phenyl]-2-pyrazolines which possess antimicrobial activity.
Parikh et. al.136 have synthesised some antimicrobial pyrazolines. Tejas Upadhyay
et. al.137 and Sohit Rajvaidya et. al.138 have prepared pyrazolines as antimicrobial
agent. A. V. Dobaria and co-workers139 has discovered pyrazolines bearing
chloroquinoline nucleus as antimicrobial agents (X).
Recently, Abd El-Galil E. Amr et. al.140 have synthesised some new 3-substituted
androstano[17,16-c]-5’-aryl-pyrazolines(XI)  and reported their antiandrogenic activity.
Asha Budakoh and co-workers141  have synthesised pyrazolines(XII)  possessing
antiamoebic activitySome of the compounds were found with IC50 lower than that of
the standard drug metronidazole and thus are better inhibitor of growth of E. histolytica.
NCH3 Cl
N
H
N
R
R = Aryl(X)
(XI)      R1,R2,R3, = Alkyl
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NR3
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H H
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Mohammad Shaharyar and co-workers142 have synthesised pyrazoline
derivativesand reported their antimycobaterial activity in vitro against mycobacterium
tuberculosis H37RV (MTB) and INH- resistant M. tuberculosis (INHR-MTB) using
agar dilution method, these compounds were found to be the most active agent against
MTB and INHR-MTB, with minimum inhibitory concentration of 0.26 µm.
With an aim to synthesise better therapeutic agents, we have investigated some
new pyrazolines to enhance the overall drug potential of resulting compounds. In our
search for new potential antimicrobial compounds, the reaction series of chalcones with
hydrazine hydrate under different conditions has been investigated and the pharmacological
profile of the compounds have been studied and described as under.
SECTION-I     : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1-ARYL-3-[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL)-
                    PYRAZOL-4'-YL]-2-PROPEN-1-ONES
SECTION-II   : SYNTHESIS AND THERAPEUTIC EVALUATION OF
3-ARYL-5-[1',N-PHENYL-3'-(2”,4”-   DICHLOROPHENYL)-
PYRAZOL-4'-YL]-PYRAZOLINES
SECTION-III : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1,N-ACETYL-3-ARYL-5- [1 ' ,N-PHENYL-3 ' - (2” ,4” -
DICHLOROPHENYL)-PYRAZOL-4'-YL]-
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-3-[1',N-
PHENYL-3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL)-2-PROPEN-1-ONES
With the biodynamic activities of chalcones and as a good synthon for various
heterocyclic rings, the interest has been focuss on the synthesis of new chalcones. With
a view to obtain compounds having better therapeutic activity, we have synthesized
1-Aryl-3-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-pyrazol-4'-yl]-2-propen-1-ones by
the condensation of 1,N-phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole with various
aromatic ketones in the presence of 40 % NaOH.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological
activities of synthesised compounds were compared with standard drugs.
The synthesised compounds have been screened for their in vitro biological assay
like antitubercular activity towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 mg/ml using Rifampin as standard drug.`
Type (I)                  R = Aryl
Cl Cl
N
N
R
O
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC  EVALUATION OF 1-ARYL-3-[1',N-
PHENYL-3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL)-2-PROPEN-1-ONES
(A) Synthesis of 2,4-Dichlorophenyl hydrazone143
A mixture of phenyl hydrazine (1.08 g, 0.01 M) and 2,4-dichloroacetophenone
(1.88 g, 0.01 M) in absolute ethanol was refluxed in water bath for 2 hrs. in the presence
of 1ml glacial acetic acid. Product obtained after cooling was crystallised from absolute
ethanol. Yield 94%, m.p. 39oC (C14H12Cl2N2; Required : C, 60.48%;H, 4.30%; N,
10.11%; Found : C, 60.23%; H, 4.33%; N,10.03%).
(B) Synthesis of 1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole144
2,4-Dichlorophenyl hydrazone(2.79 g, 0.01 M) was added into a Vilsmeier-Haack
reagent (prepared by dropwise addition of 3 ml POCl3 in ice cooled 25 ml DMF) and
refluxed for 5 hrs. The reaction mixture was poured on to crushed ice followed by
neutralization using sodium bicarbonate. Crude product was isolated and crystallised
from methanol. Yield 84%, m.p. 126oC (C16H10Cl2N2O; Required : C, 60.59%; H,
3.18%; N, 8.83%;  Found : C, 60.55%; H, 3.21%; N, 8.99%).
(C) Synthesis of 1-(p-Anisyl)-3-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-
pyrazol-4'-yl]-2-propen-1-one
To a solution of 1,N-phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole (2.17
g, 0.01 M), p-methoxyacetophenone (1.5 g, 0.01 M) in ethanol (25 ml) and 40% NaOH
added till the solution becomes basic. The reaction mixture was stirred for 24 hrs. The
contents were poured on to crushed ice. Upon neutralization the solid was separated
and crystallised from ethanol. Yield 72%, m.p.180oC (C25H18Cl2N2O2; Required :
C, 65.97; H, 4.47; N, 6.23%;  Found : C, 70.12; H, 4.41; N, 6.34%).
TLC solvent system : Ethyl acetate : Hexane (3 : 7).
Similarly other 1-aryl-3-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-pyrazol-4'-yl]-
2-propen-1-ones have been prepared. The physical data are recorded in Table No. 1.
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(D) Antimicrobial activity of 1-Aryl-3-(1',N-phenyl-3'-(2”,4”-dichlorophenyl-
pyrazol-4'-yl)-2-propen-1-ones
All the compounds have been evaluated for antimicrobial and antitubercular
activity as described under.
(a) Antimicrobial activity
Antimicrobial activity was carried out by cup-plate agar diffusion method which
has been described as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The nutrient
agar broth prepared by the usual method, was inoculated aseptically with 0.5 ml of 24
hrs. old subcultures of B. coccus, S. aureus, E.aerogenes, P. aeruginosa in separate
conical flasks at 40-50oC and mixed well by gentle shaking. About 25ml content of the
flask were poured and evenly spreaded in a petridish (13cm in diameter) and allowed to
set for 2 hrs. The cups (10 mm in diameter) were formed by the help of borer in agar
medium and filled with 0.04ml (40µg) solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also maintained
with 0.04 ml of DMF in a similar manner and the zones of inhibition of the bacterial
growth were measured in millimeter and are recorded in Graphical Chart No.1.
The antibacterial activity data of the synthesised compounds have been
compared with standard antibiotics like amoxicillin, benzoyl penicillin, ciprofloxacin and
erythromycin.
(II) Antifungal activity
A. niger was employed for testing antifungal activity using cup-plate method.
The culture was maintained on Sabouraud’s agar slants. Sterilized Sabouraud’s agar
medium was inoculated with 72 hrs. old 0.5 ml suspension of fungal spores in a separate
flask. About 25 ml of the inoculated medium was evenly spreaded in a
petridish and allowed to set for two hrs. The cups (10 mm in diameter) were punched
and filled with 0.04 ml (40 µg) solution of sample in DMF. The plates were incubated
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at 30oC for 48 hrs. After the completion of incubation period, the zones of inhibition of
growth in the form of  diameter in mm was measured. Along the test solution in each
petridish one cup was filled with solvent which acts as control. The zones of inhibition
were compared with standard antifungal Greseofulvin. The zones of inhibition are recorded
in Graphical Chart No. 1.
(b)Antitubercular activity
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordination Facility (TAACF),
U.S.A. Primary screening of the compounds for the antitubercular activity have
been conducted at 6.25 µg/ml towards Mycobacterium tuberculosis H37Rv in
BACTEC 12B using the BACTEC 460 radiometric system. The compounds
demonstrating atleast>90% inhibition in the primary screening has been tested at
lower concentration towards Mycobacterium tuberculosis H37Rv to determine the
actual minimum inhibitory concentration (MIC) in the BACTEC-460.
The antitubercular activity data have been compared with standard drug
Rifampin at 0.25 µg/ml concentration and it showed 98% inhibition.
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ANTIMICROBIAL ACTIVITY
Method : Cup-Plate145
Gram positive bacteria : Bacillus coccus
Staphylococcus aureus
Gram negative bacteria : Enterobacter aerogenes
Pseudomonas aeruginosa
Fungi : Aspergillus niger
Concentration : 40µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Benzoyl penicillin,
Ciprofloxacin, Erythromycin ,Greseofulvin
The ant imicrobial  act ivi ty  was compared with s tandard drugs viz
amoxicillin,  benzoyl penicillin, ciprofloxacin, erythromycin and antifungal activity
was compared with viz greseofulvin. The inhibition zones are measured in mm.
ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric system.
Bacteria : Mycobacterium Tuberculosis H37Rv
Concentration : 6.25 µg/ml.
Standard drug : Rifampin.
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 Observed
Alkane C-H str. (asym.) 2923 2975-2950 515
-CH3 C-H str. (sym.) 2837 2880-2860  “
C-H i.p.def. (asym.) 1450 1470-1435  “
C-H o.o.p. def. (sym.) 1358 1390-1370  “
Aromatic C-H  str. 3053 3080-3030 516
C=C str. 1596 1585-1480   “
C-H i.p. def. 1097 1125-1090   “
C-H o.o.p. def  833    835-810   “
Pyrazole C=N str. 1596 1630-1590 517
moiety                                     (overlapped)
C-N str. 1220 1230-1020  “
C-Clstr.  754    600-800 515
Ether C-O-C str. (asym.) 1259 1275-1200   “
C-O-C str. (sym.) 1031 1075-1020   “
Chalcone C=O str. 1660 1685-1645 518
CH=CH 3074 3080-3000   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
I R  S P E C T R A L  S T U D Y  O F  1 - ( p - A N I S Y L ) - 3 - [ 1 ' , N - P H E N Y L - 3 ' - ( 2 ” , 4 ” -
DICHLOROPHENYL)-PYRAZOL-4'-YL]-2-PROPEN-1-ONE
N
N
Cl
O
O
CH3
Cl
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 507.2
 580.5
 597.9
 686.6
 686.6
 734.8
 754.1 808.1
 833.2
 956.6
 981.7
1031.8
1097.4
1157.2
1170.7
1220.9
1259.4
1353.9
1406.0
1450.4
1502.4
1521.7
1596.9
1660.6
2837.1
2923.9
3053.1
3074.3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF1 - ( p - A N I S Y L ) - 3 - [ 1 ' , N - P H E N Y L - 3 ' - ( 2 ” , 4 ” -
DICHLOROPHENYL)-PYRAZOL-4'-YL]-2-PROPEN-1-ONE
Signal
  No.
Signal Position
    (δ ppm)
Relative No.
 of Protons
Multiplicity Infernce
   J Value
    In Hz
1.      3.88 3H  singlet    Ar-OCH3         -
2.      6.93 2H  doublet    Ar-Hgg’            Jgf = 8.8
3.      7.14 1H  doublet    CHj (vinylic)      Jji = 15.5
4.      7.36 2H  multiplet    Ar-Hae         -
5.      7.52 4H  multiplet   Ar-Hf, Ar-Hi,         -
  Ar-Hbb’
6.      7.60 2H  doublet   Ar-Hd    Jde = 3.2
   7.      7.77 2H  doublet   Ar-Hcc’    Jcb = 7.8
7.      7.88 2H  doublet   Ar-Hhh’    Jhg = 8.7
8.      8.32 1H  singlet   CHx          -
N
N
O
Cl
O
CH3
Cl
x
a
b
b'
c
c'
d
e
f
hh'
gg'
i
j
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EXPANDED AROMATIC REGION
Sr.
No. R    C=O str.
      1a C6H5- 1658
1b 4-OCH3-C6H4- 1660
1c 4-CH3-C6H4- 1658
1d 4-Cl-C6H4- 1655
1e 4-F-C6H4- 1663
1f 4-Br-C6H4- 1655
1g 4-OH-C6H4- 1653
1h 2-OH-C6H4- 1656
1i 4-NO2-C6H4- 1661
1j 3-NO2-C6H4- 1659
1k 2,4-(Cl)2C6H3- 1657
1l 4-NH2-C6H4- 1650
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1-ARYL-3-[1',N-PHENYL-3'-(2”,4”- DICHLOROPHENYL)-
PYRAZOL-4'-YL]-2-PROPEN-1-ONE N
N
O
Cl
O
CH3
Cl
x
a
b
b'
c
c'
d
e
f
hh'
gg'
i
j
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N
N
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O
CH3
Cl
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The antibacterial activity of chalcones (type-I) revealed that all the compounds
were able to inhibit the growth of Gram positive & Gram negative bacterial strains.
In case of Gram positive bacterial strain maximum activity was observed in
compounds bearing R = 4-fluorophenyl  and 4-bromophenyl against B. coccus. The
significant activity was displayed by compounds having R=phenyl, 2-hydroxy and 2,4-
dichlorophenyl  against S. aureus.
In case of gram negative bacterial strain all the compounds were least active
against E. aerogenes , except R= 4-methoxyphenyl and 2-hydroxyphenyl. The
compounds having R=4-hydroxyphenyl  and 2-nitrophenyl have shown good activity
against P. aeruginosa.
ANTIFUNGAL ACTIVITY
All the compound exhibited mild activity against fungal strain A. niger except
compounds having R= 4-tolyl, 4-methoxyphenyl  which showed good activity against A. niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & greseofulvin.
ANTITUBERCULAR ACTIVITY
Almost all compounds show mild activity against Mycobacterium  tuberculosis
H37Rv ranging from 0 to 72% inhibition. Compound with R = phenyl, 4-hydroxy phenyl
showed maximum activity i.e. 70% inhibition.
The antitubercular activity data have been compared with standard drug Rifampin.
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TABLE NO. 1b : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
Corp
ID
Sample
ID Comment
Assay
295646 MM-1 C6H5- Alamar H37Rv >6.25 72 -  MIC Rifampin =
 0.25 mg/ml
@ 98% Inhibition
295647 MM-2 4-OCH3-C6H4- Alamar H37Rv >6.25 57 - "
295648 MM-3 4-CH3-C6H4- Alamar H37Rv >6.25 0 - "
295649 MM-4 4-Cl-C6H4- Alamar H37Rv >6.25 23 - "
295650 MM-5 4-F-C6H4- Alamar H37Rv >6.25 66 - "
295751 MM-6 4-OH-C6H4- Alamar H37Rv >6.25 69 - "
295652 MM-7 2-OH-C6H4- Alamar H37Rv >6.25 37 - "
295653 MM-8 4-NO2--C6H4- Alamar H37Rv >6.25 12 - "
295654 MM-9 3-NO2--C6H4- Alamar H37Rv >6.25 30 - "
295655 MM-10 4-Br-C6H4- Alamar H37Rv >6.25 30 - "
295656 MM-11 4-NH2-C6H4- Alamar H37Rv >6.25 67 - "
MTb
Strain
MIC
µg/ml
%
Inhib
Where,
R =
Activity
N
N
R
O
Cl
Cl
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SECTION - II
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL-5[1',N-PHENYL-
3'(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-PYRAZOLINES
Pyrazolines constitute one of the most active class of compounds possessing
diversified biological activities. Looking at their versatile therapeutic importance and
with an aim to getting better drug, it was contemplated to synthesise some new pyrazolines
bearing 1,N-phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole nucleus. The preparation
of 3-aryl-5-(1',N-phenyl-3'-(2”,4”-dichlorophenyl-pyrazol-4'-yl)-pyrazolines (II) have
been undertaken by cyclocondensation of chalcones of type (I) with hydrazine hydrate
in glacial acetic acid.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
N
N
Cl
R
O
Cl
N
N
NH N
R
Cl Cl
NH2NH2H2O
Type (II)    R = Aryl
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL-5[1',N-PHENYL-
3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-PYRAZOLINES
(A) Synthesis of 2,4-Dichlorophenylhydrazone143
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole144
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-Anisyl)-3-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-
pyrazol-4'-yl]-2-propen-1-one
See [A] Part-I, Section-I (C).
(D)  Synthesis of 3-(p-Anisyl)-5-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-
 pyrazol-4'-yl]-pyrazoline
 A mixture of 1-(p-anisyl)-3-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-pyrazol-
4'-yl]-2-propen-1-one (4.49 g, 0.01 M) in 25 ml absolute alcohol,  hydrazine hydrate
(1 g, 0.02 M)  was refluxed for 8 hrs. The reaction mixture was poured on to crushed
ice. The product was isolated and crystallised from ethanol. Yield 60%, m.p. 170oC
(C25H20Cl2N4O; Required : C, 64.80; H, 4.35; N, 12.09%;  Found : C, 64.78; H,
4.38; N, 12.28%).
TLC solvent system : Acetone : Benzene (2 : 8).
Similarly other substituted pyrazolines have been prepared. The physical
data are recorded in Table No. 2.
(E) Antimicrobial activity of 3-Aryl-5-[1',N-phenyl-3'-(2”,4”-dichlorophenyl-
pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 2.
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IR SPECTRAL STUDY OF 1,N-ACETYL-3-(P-ANISYL)-5-[1',N-PHENYL-3'-(2”,4’-
DICHLOROPHENYL)-PYRAZOL-4'-YL]-PYRAZOLINE
N
N
NH
N
Cl Cl
O
CH3
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
110.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 457.1
 478.3
 497.6
 515.0
 594.0
 642.3
 686.6
 759.9
 777.3
 810.0
 914.2
 958.6
1018.3
1056.9
1124.4
1180.4
1215.1
1247.9
1280.6
1315.4
1365.5
1407.9
1452.3
1500.5
1552.6
1596.9
2229.6
2856.4
2912.3
3024.23406.1
 Observed
Alkane C-H str. (asym.) 2912 2975-2950 515
-CH3 C-H str. (sym.) 2856 2880-2860   “
C-H i.p.def. (asym.) 1452 1470-1435   “
C-H o.o.p. def. (sym.) 1365 1390-1370   “
Aromatic C-H  str. 3024 3080-3030 516
C=C str. 1552 1585-1480   “
C-H i.p. def. 1124 1125-1090   “
C-H o.o.p. def  810    835-810   “
Pyrazole C=N str. 1596 1630-1590 517
moiety C-N str. 1056 1230-1020   “
C-Cl str.   759    830-560
Ether C-O-C str. (asym.) 1247 1275-1200 515
C-O-C str. (sym.) 1018 1075-1020   “
Pyrazoline C=N str. 1596 1630-1590 519
                                     (overlapped)
C-N str.                              1180 1230-1020   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
50Pyrazolines...
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 1,N-ACETYL-3-(P-ANISYL)-5-[1',N-PHENYL-3'-(2”,4”-
DICHLOROPHENYL)-PYRAZOL-4'-YL]-PYRAZOLINE
N
N
NH N
Cl
H H
Cl
O
CH3
cb
a
b' c'
d
e
f
x
g
g'h'
h
j
i
k
Signal
  No.
Signal Position
    (δ ppm)
 RelativeNo.
  of Protons
Multiplicity Inference
   J Value
    In Hz
1.      2.99                1H  double        CHi        -
 doublet
2.      3.33                1H  double        CHj                  -
 doublet
3.      3.85                3H  singlet        Ar-OCH3
4.      4.76                1H  double        CHk        -
 doublet
5.      6.94                2H  doublet       Ar-Hgg’             Jgh = 9.0
   6.      7.30                2H  multiplet     Ar-Ha+ Ar-He        -
7.      7.43                3H  triplet         Ar-Hf+Ar-Hbb’        -
8.      7.50                1H  doublet       Ar-Hd  Jde = 1.9
9.      7.55                2H  doublet       Ar-Hcc’            Jcc’ = 8.7
   10.      7.74                2H  doublet       Ar-Hhh’  Jhg= 9.1
   11.      8.04                1H  singlet        Ar-Hx        -
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EXPANDED AROMATIC REGION
N
N
NH N
Cl
H H
Cl
O
CH3
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a
b' c'
d
e
f
x
g
g'h'
h
j
i
k
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data, it has been observed that the compounds bearing
R=4-methylphenyl ,2-hydroxyphenyl have displayed significant activity against B.coccus.
The compounds bearing R=2-bromophenyl, 4-hydroxyphenyl have shown good activity
against S. aureus.
In case of Gram negative bacterial strains, the compounds with R=phenyl and 4-
hydroxyphenyl have shown considerable activity against E. aerogenes. The maximum
activity was displayed by the compounds bearing R=2-fluorophenyl, 2-hydroxyphenyl
and3-nitrophenyl P. aeruginosa..
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested
species. However, the compounds having R=4-chlorophenyl,4-hydroxyphenyl have
displayed highest activity against A.niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like amoxycillin, benzoylpenicillin, ciprofloxacin, erythromycin & greseofulvin.
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SECTION - III
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-ARYL-5-
[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-PYRAZOLINES
The growing potent literature of recent years demonstrated that pyrazoline ring
system is having interesting pharmacological activity.Looking to the diversified biological
activities of pyrazolines, it was considered worthwhile to synthesise a series of pyrazolines
of type-(III) bearing pyrazole nucleus by the condensation of 1-aryl-3-[1’,N-phenyl-
3’(2”,4”-dichlorophenyl)-pyrazol-4’-yl]-2propen-1-ones with   phenyl hydrazine in glacial
aceti acid.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The biological
activities of the synthesised compounds were compared with standard drugs.
gl. CH3COOH
NH2NH2H2O
N
N
R
O
Cl Cl
N
N
Cl Cl
N
N R
O
CH3
Type (III)    R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-ARYL-5-
[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-PYRAZOLINES
(A) Synthesis of 2,4-Dichlorophenylhydrazone143
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole144
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-Anisyl)-3-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-
pyrazol-4'-yl]-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthesis of 1,N-Acetyl-3-(p-anisyl)-5-[1',N-phenyl-3'-(2”,4”-dichloro-
phenyl)-pyrazol-4'-yl]-pyrazoline
 A mixture of 1-(p-Anisyl)-3-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-pyrazol-
4'-yl]-2-propen-1-one (4.49 g, 0.01 M) in 25 ml absolute alcohol,, hydrazine hydrate
(1 g, 0.02 M) and glacial acetic acid (10 ml) was refluxed for 12 hrs. The reaction
mixture was poured on to crushed ice. The product was isolated and crystallised from
ethanol. Yield 68%, m.p. 148oC (C27H22Cl2N4O2; Required : C, 64.17%; H, 4.39%;
N, 11.09%;  Found : C, 64.11%; H, 4.35%; N, 11.23%).
TLC solvent system : Acetone : Benzene (1 : 9).
Similarly other substituted pyrazolines have been prepared. The physical
data are recorded in Table No. 3.
(E) Antimicrobial activity of 3-Aryl-5-[1',N-phenyl-3'-(2”,4”-dichlorophenyl-
pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 3.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1 ,N-ACETYL-3-(P-ANISYL)-5- [1 ' ,N-PHENYL-3' -
(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-PYRAZOLINE
 Observed
Alkane C-H str. (asym.) 2923 2975-2950 515
-CH3 C-H str. (sym.) 2852 2880-2860   “
C-H i.p.def. (asym.) 1415 1470-1400   “
C-H o.o.p. def. (sym.) 1361 1390-1370   “
Aromatic C-H  str. 3064 3080-3030 516
C=C str. 1554 1585-1480   “
C-H i.p. def. 1101 1125-1090   “
C-H o.o.p. def  827    835-810   “
Pyrazole C=N str. 1596 1630-1590 517
moiety C-N str. 1058 1230-1020   “
C-Cl str.  758    830-560   “
Ether C-O-C str. (asym.) 1247 1275-1200 515
C-O-C str. (sym.) 1076 1075-1020   “
Pyrazoline C=O str. 1670 1760-1650 519
C=N str. 1596 1630-1560   “
                                    (overlapped)
C-N str.                              1180 1230-1020   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
20.0
40.0
60.0
80.0
100.0
%T
750.01000.01250.01500.01750.02000.03250.0
 690.5
 758.0
 827.4
 862.1
 960.5
1058.8
1076.2
1101.3
1222.8
1247.9
1361.7
1415.7
1502.4
1554.5
1596.9
1670.2
2852.5
2923.9
3060.8
3259.5
N
N
N
N
Cl Cl
O
CH3
O
CH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 1,N-ACETYL-3-(P-ANISYL)-5-[1' ,N-PHENYL-3'-
(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-PYRAZOLINE
N
N
N N
Cl
H H
Cl
O
CH3
O
CH3
cb
a
b' c'
d
e
f
x
g
g'h'
h
j
i
k
Signal
  No.
Signal Position
    (δ ppm)
 RelativeNo.
 of Protons
Multiplicity Inference    J Value
    In Hz
 1.       2.31 3H  singlet COCH3         -
 2.       3.15 1H  double CHi         -
 doublet
 3.       3.53 1H  double CHj         -
 doublet
 4.       3.86 3H  singlet Ar-OCH3         -
 5.       5.52 1H  double CHk         -
 doublet
 6.       6.90 2H  doublet Ar-Hgg’    Jgh = 8.7
    7.       7.22 2H  multiplet Ar-Hae          -
 8.       7.33 1H  doublet Ar-Hd    Jde = 1.9
 9.       7.41 3H   multiplet Ar-Hf,Ar-Hbb’          -
    10.       7.52 2H  doublet Ar-Hcc’    Jcb = 8.8
    11.       7.68 2H  doublet Ar-Hhh’    Jhg = 8.7
    12.       7.93 1H  singlet Ar-Hx         -
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EXPANDED AROMATIC REGION
Sr.
No. R    C=O str.
      3a C6H5- 1665
3b 4-OCH3-C6H4- 1670
3c 4-CH3-C6H4- 1668
3d 4-Cl-C6H4- 1672
3e 4-F-C6H4- 1666
3f 4-Br-C6H4- 1669
3g 4-OH-C6H4- 1667
3h 2-OH-C6H4- 1662
3i 4-NO2-C6H4- 1668
3j 3-NO2-C6H4- 1673
3k 2,4-(Cl)2C6H3- 1662
3l 4-NH2-C6H4- 1667
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1,N-ACETYL-3-ARYL-5-[1',N-PHENYL-3'-(2”,4”-
DICHLOROPHENYL)-PYRAZOL-4'-YL]-PYRAZOLINES
N
N
N N
Cl
H H
Cl
O
CH3
O
CH3
cb
a
b' c'
d
e
f
x
g
g'h'
h
j
i
k
N
N
N
N
Cl Cl
O
CH3
O
CH3
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051015202530
ZONE OF INHIBITION IN mm B.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type
(III) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However, the maximum activity was observed in compounds bearing
R=4-hydroxyphenyl, 3-nitrophenyl and 2,4-dichloronphenyl substituents against B.coccus.
The significant activity was observed in compounds bearing R=4-chlorophenyl and 2-
hydroxyphenyl against S.aureus.
The maximum activity was displayed by the compounds bearing R=phenyl and
4-bromophenyl against E. aerogenes. In case of P. aeroginosa all the compounds
were least active except R=4-methylphenyland 4-bromophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal
strain. However mild activity was shown by the compounds bearing R=3-nitrophenyl
against A.niger.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared with
standard drug viz. greseofulvin.

66Pyrimidines...
INTRODUCTION
Pyrimidine is the most important member of all the diazine as this ring system
occurs widely in living organisms. Pyrimidine was first isolated by Gabriel and Colman
in 1899. Pyrimidines  represent one of the most active class of compounds possessing a
wide spectrum of biological activities.
Pyrimidine and its derivatives have gained prominence because of their potential
pharmaceutical values. Many pyrimidine derivatives play vital role in many physiological
processes. They are among those molecules that make life possible as being some part
of the building blocks of DNA and RNA. Pyrimidine is considered to be a resonance
hybrid of the charged and uncharged canonical structures, its resonance energy has been
found to be less than benzene or pyridine.
Some pyrimidines of physiologically as well as pharmacological importance are
as above: e.g. cytosine (I), beclmethrin (II), blasticidin (III). Synthetic pyrimidinone
derivatives contribute much to the searchable literature of pyrimidinone derivatives, in
huge libraries owing to their wide applicability in different fields.
SYNTHETIC ASPECTS
Different methods for the synthesis of pyrimidinones have been cited in the
literature.146
1. Wang jinjum147 have prepared some novel benzo-[C]-pyrano-[4,3-d]-pyrimidine
derivatives.
N
N
NH2
O
CH3
CH2OH O
NH
O NH2
CH3
NH
NH2
COOH
O
  (II) (III)  (I)
N
H
N
O
NH2
2. Biginelli148 investigated that condensation of aromatic aldehyde with β-ketoester
and urea or thiourea  yield the pyrimidine derivatives.
3. Hussain Ali Saleiman et. al.149 have prepared oxoyrimidine derivatives(IV) by
using urea in alcoholic KOH.
4. V. Alagarsamy et. al.150 have prepared pyrimidines from thiosemicarbazide.
H5C2OOC
CH3
O
Ph-CHO,H2O
NH2 NH2
O
N
H
N
H
Ph
H5C2OOC
CH3
O
O
O
R
X
NH2 NH2
O
NHNH
X
R
X = O or S
N
N N
RO
CH3
Alco.KOH
Urea N
N N
CH3
NH NH
R
O
S
NH
CH3
CH3
O
OEt
NH
NH2
S
S
N
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5. Deepak Prajapati et. al.151 have synthesised pyrimidine from 6-[(dimethylamino)
methylene] amino uracil.
6. By the condensation  of  α-keto ester with thiourea and aldehyde152.
MECHANISM
THERAPEUTIC IMPORTANCE
Pyrimidine derivatives have been proved to be of great importance in exhibiting
and enhancing the biological activities such as
COOEt
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+
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1. Antileshmenia153
2. Anthelmintic154
3. Antagonists155-157
4. Antiinflammatory and anticonvulsant158,159
5. Antitumor160
6. Herbicidal161
7. Antimalarial162
8. AntiHIV163,164
9. Antithyroid165
10. Antiviral166
11. Antimicrobial167
12. Diuretic168
13. Tranquilizer169
Timothy and co-workers170 have suggested imidazolyl pyrimidinones as antiviral.
Yi-Meen Chou et. al.171 have synthesised bithienyl-pyrimidine derivatives (I) and
reported them as antitumor agents. Bharat Hagu et.al.172 have synthesised pyrimidinones
and reported them as α1a- adrenergic receptor antagonist.Michael F. Jarvis et. al.173
have investigated analgesic and antiinflammatory effects of A-286501(II). A-286501 is
structurally novel Ak inhibitor. Maurizio Botta et.al.174 have synthesised pyrimidinones
by solid phase synthesis and tested in vitro for their ability to inhibit HIV-1RT in
comparison with nevirapine.
Barbuliene M. M. et. al.175 have synthesised pyrimidinones as antiinflammatory
agent.Lagu Bharat et. al.176 have investigated pyrimidine derivatives showing antagonist
for melanine conc. hormone receptor. El-Agrody A. M. et. al.177 have studied
S
S
N N
Cl
(I)
N+
NN
NH2
Br
OH
OH NH2
(II)
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antimicrobial activity of pyrimidines.Isaac O. Donkor et.al.178  have synthesised
pyrimidine derivatives (III) and  reported as inhibitors of dihydroflate reductase (DHFR)
from pneum cystis carinil, toxo plasma gondii, mycobacterium avium amd rat liver.
Adnan A. Bekhit et. al.179 have designed and synthesised some 1H-pyrazolyl-
thiazolo[4,5-d] pyrimidines as antiinflammatory-antimicrobial agents.
Jie Yang and co-workers180 have synthesised pyrimidine derivatives as inhibitors
of receptor tyrosin kinase (RTK), inhibition of this RTKs has provided new paradigm in
the treatment of tumors and also angiogenesis.Amjad Ali et. al.181 have synthesised
new fused pyrimidinones as antimicrobial agents.Tsann-Long Su et. al.182 have reported
pyrimidines (IV) as antitumor agents.
Sushilkumar and co-workers183 have synthesised thiopyrimidines(V) and
reported them as antiinflammatory agents. David White et.al.184 have documented
anticonvulsant activity of pyrimidinone derivatives. Leach Kozerski et.al.185 have
investigated pyrimidines as antitumor agents.Novel 5-substituted, 2,4-diaminofuro[2,3-d]
pyrimidines(VI) as multireceptor tyrosine kinase and dihydrofolate reductasee inhibitors
with antiangiogenic and antitumor activity has been reported. Anu Agarwal and
co-workers186  have synthesised trisubstituted pyrimidines and reported  them as
antimalarial and antitubercular agents. Compounds have shown antimalarial activity against
plasmodium falciparum in the range of 0.25-0.2mg/ml and antitubercular activity against
mycobacterium tuberculosis H37Ra at a concentration of  12.5 µg/ml.
N
N NH
H3CO OCH3
OCH3
NH2
NH2 Me
R1 = NH2, OH
R2 = H, Me, NO2
NN
NH2
NH2
R1
NR2
(III) (IV)
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`Andreas Kling et.al.187 have synthesised pyrimidinones and reportem as potential
antidepressant drugs. Pyrimidine analogues were tested in vitro against three cancer
cell lines, MCF7(breast), NCI-H460(lung) and SF-268(CNS).Panteha et.al.188 have
demonstrated pyrimidine derivatives as anticancer,antiviral agents.A novel class of furo
[2,3-d} pyrimidines(VII) has been discovered as potent dual inhibitors of Tie-2 and
VEGFR2 receptor tyrosine kinase (TK) by Yasushi Miyazaki et.al.189.
Recently, Naveen Chandra and co-workers190 have synthesised some aryl
substituted terpenyl pyrimidines(VIII) and reported their antileishmanial activity.Antonello
Mai et. al.191 have synthesised pyrimidine derivative as non-nucleoside reverse
transcriptase inhibitors.Marcus H. Holschbach et.al.192 have reported pyrimidine
derivatives(IX) potential A2A adenosine receptor anmtagonists for positron emission
tmography (PET). Mar ia  T.  Cocco and co-workers193 have  synthes ised
hydrazinopyrimidine-5-carbonitrile derivatives and reported their antitumor activity.
Pyrimidine derivatives demonstrated inhibitory effects on the growth of a wide range of
cancer cell lines generally at 10-7M concentration.Rudolf Waelchli et. al.194 have
synthesised pyrimidine derivatives as IKK inhibitors. Pyrimidine derivatives are identified
N
N
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CH3
R
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as good inhibitors of IKK2 with IC50 values of 40 and 25 nM.
Thus, diverse biological activities have been encountered in compounds containing
pyrimidinone ring system. To further assess the potential of such type of compounds,
study of pyrimidinones have been carried out as under.
SECTION - I :  SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-
ARYLIMINO-3,N-ARYL-5-[1, 'N-PHENYL-3'(2”,4”-
DICHLOROPHENYL)-4'-PYRAZOLYL-METHINO]-4-
THIAZOLIDINONES
SECTON- II :  SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-
ARYLIMINO-7,N-ARYL-2-OXO-4-[1',N-PHENYL-3'-
(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-1,2,3,4-
TETRAHYDROTHIAZOLIDINO-[4,5-e]-PYRIMIDINES
SECTON- II :  SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-
ARYLIMINO-7,N-ARYL-2-THIO-4-[1',N-PHENYL-3'-
(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-1,2,3,4-
TETRAHYDROTHIAZOLIDINO-[4,5-e]-PYRIMIDINES
CH3
CH3
CH3
N
N
N O
O2N
N
N
NH
O
NH2
NH
R1
R2
(VIII)
R1 = Ar(CH2)2
R2 = 2-furyl, 3-furyl
(IX)
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-ARYLIMINO-3,N-
ARYL-5-[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL)-4'-PYRAZOLYL
METHINO]-4-THIAZOLIDINONES
Recently much interest has been focused on the synthesis and biodynamic activities
of arylidene and it is a good synthon for constructing various heterocyclic rings. With a
view to obtaining compounds having better therapeutic activities, we have synthesised
2-arylimino-3-N-aryl-5-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-4'-pyrazol methino]-4-
thiazolidinones by the condensation of pyrazole aldehyde with various thiazolidinone
derivatives.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
mass spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at concentration of 6.25 mg/ml using Rifampin as standard drug.
R = ArylType - (IV)
S
N
N
N
Cl
NR R
O
Cl
CH3COOH /
CH3COONa
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N
N
R
R
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N
N
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ClCl
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REACTION SCHEME
Type - (IV) R = Aryl
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Cl
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R
O
Cl
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S
N
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R
O
+ N
N
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ClCl
gl. ACOH
CH3COONa
gl. ACOH
Cl.CH2COOH
R
NH
S
NH
R
Absolute alcohol
2.NH2 R + CS2
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-ARYLIMINO-3,N-
ARYL-5-[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL)-4'-PYRAZOLYL
METHINO]-4-THIAZOLIDINONES
[A] Preparation of N1, N3-Bis-p-anisyl thiourea195
In a round bottom flask, a mixture of p-anisidine (0.2M), carbon disulphide (7ml,
0.01M) and absolute alcohol was refluxed for 5-6 hrs. at  40oC. On completion of
reaction, the excess of carbon disulphide and alcohol was removed by distillation. The
product was treated with hydrochloric acid to remove excess of amine present and
crude product was isolated and crystallised from ethanol. m.p.190 oC.
[B] Preparation of 2-p-Anisylimino-3-p-anisyl-5H-4-thiazolidinones196
A solution of N1, N3-bis-p-anisyl thiourea (0.01M) and chloroacetic acid (0.94g,
0.01M) in glacial acetic acid (15 ml) was refluxed with fused sodium acetate (1.25g,
0.015M) for 8 hrs. The reaction product was poured in water, kept overnight, crude
product was isolated and crystallised from ethanol. m.p. 168oC.
[C] Preparation of 2-(p-Anisylimino)-3-(p-anisyl)-5-[1',N-phenyl-3'-(2”,4”-
dichlorophenyl)-4'-pyrazolylmethino]-4-thiazolidinone
A mixture of 2-(p-anisylimino)-3-(p-anisyl)-5H-4-thiazolidinone (3.28g, 0.01M)
1,N-phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole (3.17g, 0.01M) and fused
sodium acetate (1.25g, 0.015M) was refluxed in glacial acetic acid (15 ml) for 9-10
hrs. at temp 120oC. cooled, poured into water and treated with ammonia to remove
excess of glacial acetic acid. The product was isolated and crystallised from ethanol.
yield 79% m.p. 186oC (C33H24Cl2N4O3S : Found : C, 63.16%; H, 3.85%; N, 8.93%
Requires : C, 63.14%; H, 3.88%; N, 9.16%).
TLC solvent system : Acetone : Benzene (2 : 8).
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Similarly other substituted thiazolidinones have been prepared. The physical data
are recorded in Table No. 4.
[D] Therapeutic activity of 2-Arylimino-3,N-aryl-5-[1',N-phenyl-3'-(2”,4”-
dichlorophenyl)-4'-pyrazolylmethino]-4-thiazolidinones
Antimicrobial testing was carried out as described in [a] Part-I, Section-I (D).
The zone of inhibition of the test solution are recorded in Graphical Chart No.4.
The antitubercular  screening of the compounds of type(IV) were carried
out by TAACF, the Southern Research Institute, U.S.A. as described In [b] Part-I,
Section-I (D) and the percentage of inhibition data of the compounds are recorded
in Table No. 4a.
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IR SPECTRAL STUDY OF 2-(P-ANISYL)IMINO-3,N-(P-ANISYL)5-[1’,N-PHENYL-
3’-(2”,4”-DICHLOROPHENYL)-4’-PYRAZOLYLMETHINO]-4-THIAZOLIDINONES
0.0
20.0
40.0
60.0
80.0
100.0
%T
750.01000.01250.01500.01750.02000.03250.0
 686.6
 717.5
 754.1
 798.5
 829.3
 889.1
 954.7
1016.4
1076.2
1101.3
1164.9
1209.3
1228.6
1355.9
1411.8
1433.0
1504.4
1535.2
1600.8
1637.5
1712.7
2339.5
2858.3
2922.0
3057.0
3404.1
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
 Observed
Alkane C-H str. (asym.) 2922 2975-2950 515
-CH3 C-H str. (sym.) 2858 2880-2860   “
C-H i.p.def. (asym.) 1433 1470-1435   “
Aromatic C-H str. 3057 3080-3030   “
C=C str. 1504 1585-1480 516
C-H i.p. def. 1101 1125-1090   “
C-H o.o.p. def  829    835-810   “
Pyrazole C=N str. 1600 1630-1590 517
moiety C-N str. 1164 1230-1020   “
C-Cl  754    830-560   “
Ether C-O-C str. (asym.) 1228 1275-1200 515
C-O-C str. (sym.) 1076 1075-1020   “
Thiazolidinone C=O str. 1712 1760-1655 520
ring C=N str. 1585 1650-1590   “
C-S-C str.  686    700-600   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
S
N
N
N
Cl
N
O
Cl
O
CH3
O
CH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 2-(P-ANISYL)IMINO-3,N-(P-ANISYL)-5-[1’,N-PHENYL-
3’-(2”,4”-DICHLOROPHENYL)-4’-PYRAZOLYLMETHINO]-4-THIAZOLIDINONES
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1.    3.62 6H  singlet Ar-OCH3 ,
Ar-OCH3          -
2.    6.91 4H  singlet ArHgg’+Hjj’          -
3.    7.00 2H  doublet ArHhh’    Jhg = 8.0
4.    7.36 4H  multiplet Ar-Ha,Ar-He,          -
Ar-Hf,Ar-Hk
5.    7.42 2H  doublet Ar-Hbb’    Jbc = 8.2
6.    7.48 2H  doublet Ar-Hcc’              Jcb = 8.0
7.    7.53 1H  doublet Ar-Hd    Jde = 1.9
8.    7.74 2H  doublet Ar-Hii’    Jij =  8.0
9.    8.09 1H  singlet Ar-Hx         -
S
N
N
N
Cl
N
O
Cl
O
CH3
O
CH3
a
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c
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d
e
f
h
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g
g'
i
i'
j
j'
k
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EXPANDED AROMATIC REGION
IR SPECTRAL STUDY OF 2-ARYLIMINO-3,N-ARYL-5-[1’,N-PHENYL-3’-(2”,4”-
DICHLOROPHENYL)-4’PYRAZOLYLMETHINO]-4-THIAZOLIDINONES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R
      4a C6H5- 1708
4b 4-OCH3-C6H4- 1712
4c 4-CH3-C6H4- 1706
4d 4-F-C6H4- 1710
4e 4-Cl-C6H4- 1714
4f 4-Br-C6H4- 1705
4g 2-NO2-C6H4- 1708
4h 3-NO2-C6H4- 1710
4i 3-Cl,4-F-C6H3- 1715
4j 2,4-(Cl)2-C6H3- 1712
4k 3,4-(Cl)2-C6H3- 1710
4l 2-CH3-C6H4- 1712
C=Ο str.S N
N
N
Cl
N
O
Cl
O
CH3
O
CH3
a
b
b'
c
c'
d
e
f
h
h'
g
g'
i
i'
j
j'
k
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that the compounds bearing
R=2-methoxyphenyl and 4-chlorophenyl have displayed good activity against B.coccus.
The compounds bearing R=4-tolyl, 3-nitrophenyl and 3-chloro 4-fluorophenyl have shown
considerable activity against S.aureus.
In case of Gram negative bacterial strains all the compounds were inactive against
E.aerogenes except the compound bearing R=phenyl, 4-bromophenyl. While the
compounds bearing R=2,4-dichlorophenyl showed significant activity against
P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested
species. However, the compounds having R=4-methoxyphenyl, 2-nitrophenyl and
3,4-dichlorophenyl displayed highest activity against A.niger.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared
with standard drug viz. greseofulvin.
ANTITUBERCULAR ACTIVITY
All  the compounds displayed mild ant i tubercular  act ivi ty  against
Mycobacterium tuberculosis H37Rv i.e. 0 to 41% inhibition.
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TABLE NO. 4b : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
Corp
ID
Sample
ID Comment
Assay
295657 MM-12 C6H5- Alamar H37Rv >6.25 0 - MIC Rifampin =
0.25 mg/ml
@ 98% Inhibition
295658 MM-13 4-OCH3-C6H4- Alamar H37Rv >6.25 10 - "
295659 MM-14 4-CH3-C6H4- Alamar H37Rv >6.25 41 - "
295660 MM-15 4-F-C6H4- Alamar H37Rv >6.25 36 - "
295661 MM-16 3-Cl,4-F-C6H3- Alamar H37Rv >6.25 19 - "
295662 MM-17 3-NO2-C6H4- Alamar H37Rv >6.25 17 - "
295663 MM-18 2-NO2-C6H4- Alamar H37Rv >6.25 25 - "
295664 MM-19 3,4-(Cl)2-C6H3- Alamar H37Rv >6.25 9 - "
295665 MM-20 4-Br-C6H4- Alamar H37Rv >6.25 7 - "
295666 MM-21 2,4-(Cl)2-C6H3- Alamar H37Rv >6.25 17 - "
MTb
Strain
MIC
µg/ml
%
Inhib
Where,
R =
Activity
S
N
N
N
Cl
N
O
Cl
R
R
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SECTION - II
SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYLIMINO-7,N-ARYL-2-
OXO-4-[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL) PYRAZOL-4'-YL],1,2,3,4-
TETRAHYDRO THIAZOLIDINO-[4,5-e]-PYRIMIDINES
Many pyrimidinone derivatives are associated with diversified biological
properties. It was thought of interest that a pyrimidinone ring couple to pyrazole
nucleus and thiazolidinone nucleus, the resulting compounds may possess significant
biological potency.Pyrimidinones of typ (V) have been prepared by the condensation
of 2-arylimino-3-aryl-5H-4-thiazolidinone with 1,N-phenyl-3-(2’,4’-dichlorophenyl)-
4-formyl-pyrazole and urea in glacial aceticacid with fused sodium acetate.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The
biological activities of synthesised compounds were compared with standard drugs.
N
N
CHO
ClCl
S
N
N
R
R
O+
NH2 NH2
O
H++
N N
ClNH
N
H
S
N
N
R
R
O
Cl
R = ArylType - (V)
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYLIMINO-7,N-ARYL-
2-OXO-4-[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-
1,2,3,4-TETRAHYDRO-THIAZOLIDINO-[4,5-e]-PYRIMIDINES
[A] Preparation of 2-p-anisylimino-3-anisyl-5H-4-thiazolidinone
See, Part-II, Section-I (B)
[B] Preparation of 6-(p-anisylimino)-7,N-(p-anisyl)-2-oxo-4-(1',N-phenyl-3'-
(2”,4”-dichlorophenyl-pyrazol-4'-yl)-1,2,3,4 tetrahydro thiazolidino-[4,5-e]-
pyrimidine
A mixture of 2-(p-anisylimino)-3-(p-anisyl)-5H-4-thiazolidinone (3.28g, 0.01M),
1,N-phenyl-3-(2’,4’-dichlorophenyl)-4-formyl-pyrazole (3.17g, 0.01M)and urea (0.60g,
0.01M) were taken in glacial acetic acid (20 ml) with fused sodium aetate(1.25gm,
0.015M). The reaction mixture was refluxed for 10 hrs. cooled, poured into crushed ice.
The product was isolated and crystallised from methanol-DMF. Yield 72%, m.p. 232oC
(C34H26Cl2N6O3S, Found : C, 60.99%; H, 3.91%; N, 12.55% Requires : C, 61.02%;
H,3.88%; N, 12.68%;).
TLC solvent system : Ethyl acetate : Hexane (1.8 : 8.2).
Similarly other pyrimidines were prepared. The physical data are recorded
in Table No. 5.
[C] Therapeutic activity of 6-Arylimino-7,N-aryl-2-oxo-4-[1',N-phenyl-3'-
(2”,4”-dichlorophenyl)-pyrazol-4'-yl]-1,2,3,4-tetrahydro-thiazolidino-
(4,5-e)-pyrimidines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 5.
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IR SPECTRAL STUDY OF  6-(P-ANISYL)IMINO-7,N-(P-ANISYL)2-OXO-4-[1’,N-PHENYL-
3’-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4’YL]-1,2,3,4-TETRAHYDROTHIAZOLIDINO-
[4,5-E]-PYRIMIDINES.
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
 Observed
Alkane C-H str. (asym.) 2923 2975-2950 515
-CH3 C-H str. (sym.) 2823 2880-2860   “
C-H i.p.def. (asym.) 1417 1470-1435   “
Aromatic C-H str. 3080 3080-3030   “
C=C str. 1514 1585-1480 516
C-H i.p. def. 1076 1125-1090   “
C-H o.o.p. def  829    835-810   “
Pyrazole C=N str. 1600 1630-1590 517
moiety C-N str. 1205 1230-1020   “
C-Cl str.  777    830-560 515
Ether C-O-C str. (asym.) 1249 1275-1200   “
C-O-C str. (sym.) 1041 1075-1020   “
Pyrimidine C=O str. 1678 1750-1600 521
     ring N-H str. 3377 3500-3350   “
C=N str. 1629 1650-1550   “
C-S-C str. 1132 1000-1200   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/
 513.0
 563.2
 626.8
 677.0
 705.9
 777.3
 810.0
 829.3
 885.3
 935.4
 968.2
1041.5
1076.2
1132.1
1205.4
1249.8
1299.9
1353.9
1380.9
1417.6
1479.3
1514.0
1564.2
1600.8
1629.7
1676.0
2823.6
2923.9
3080.1
3377.1
N N
Cl
NH
N
H
S
N
N
O
H3CO
H3CO
Cl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF  6-(P-ANISYL)IMINO-7,N-(P-ANISYL)2-OXO-4-[1’,N-PHENYL-
3’-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4’YL]-1,2,3,4-TETRAHYDROTHIAZOLIDINO-
[4,5-E]-PYRIMIDINES.
N N
Cl
NH
N
H
S
N
N
O
H3CO
H3CO
Cl
a b
b'
c
c'
d
e
f
h
h'g
g'
i
i'
j
j' k
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.83 6H singlet Ar-OCH3,
Ar-OCH3
2. 6.92 4H singlet Ar-Hgg’,Ar-Hjj’         -
3. 7.03 2H doublet Ar-Hhh’   Jhg = 8.8
4. 7.36-7.39 4H doublet Ar-Ha,Ar-He,         -
Ar-Hf,Ar-Hk
5. 7.36 2H doublet Ar-Hbb’   Jbb’= 8.4
6. 7.39 2H doublet Ar-Hcc’             Jcb = 8.1
7. 7.54 1H doublet Ar-Hd   Jde = 1.9
8. 7.75 2H doublet Ar-Hii’   Jij =  8.9
9. 8.09 1H singlet Ar-Hx        -
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EXPANDED AROMATIC REGION
IR SPECTRAL STUDY OF  6-ARYLIMINO-7,N-ARYL-2-OXO-4-[1',N-PHENYL-3'-(2”,4”-
DICHLOROPHENYL) PYRAZOL-4'-YL],1,2,3,4-TETRAHYDRO THIAZOLIDINO-
[4,5-e]-PYRIMIDINES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R
      5a C6H5- 1680
5b 4-OCH3-C6H4- 1676
5c 4-CH3-C6H4- 1685
5d 4-F-C6H4- 1682
5e 4-Cl-C6H4- 1670
5f 4-Br-C6H4- 1688
5g 2-NO2-C6H4- 1684
5h 3-NO2-C6H4- 1690
5i 3-Cl,4-F-C6H3- 1678
5j 2,4-(Cl)2-C6H3- 1682
5k 3,4-(Cl)2-C6H3- 1682
5l 2-CH3-C6H4- 1677
C=Ο str.
N N
Cl
NH
N
H
S
N
N
O
H3CO
H3CO
Cl
a b
b'
c
c'
d
e
f
h
h'g
g'
i
i'
j
j' k
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N N
Cl
NH
N
H
S
N
N
O
H3CO
H3CO
Cl
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051015202530
ZONE OF INHIBITION IN mm B.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that the compounds bearing
R=phenyl and 2-nitrophenyl have displayed good activity against B.coccus. The
compounds bearing R=4-tolyl, 2-nitrophenyl and 3-nitrophenyl have shown considerable
activity against S.aureus.
In case of Gram negative bacterial strains all the compounds were inactive against
E.aerogenes except the compound bearing R=4-bromophenyl. While the compounds
bearing R=phenyl, 2-nitrophenyl and 2-tolyl showed significant activity against
P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested
species. However, the compounds having R=4-methoxyphenyl and 3-nitrophenyl
displayed highest activity against A.niger.
` The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity wascompared
with standard drug viz. greseofulvin.
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SECTION - III
SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYLIMINO-7,N-ARYL-
2-THIO-4-[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL) PYRAZOL-4'-YL],1,2,3,4-
TETRAHYDRO THIAZOLIDINO-[4,5-e]-PYRIMIDINES
In the past years considerable evidence has been accumulated to demonstrate
the efficiency of pyrimidinones. It was considered worthwhile to synthesise
thiopyrimidines of type (VI), which have been prepared by the condensation of 2-
arylimino-3-aryl-5H-4-thiazolidinone with 1,N-phenyl-3-(2’,4’-dichlorophenyl)-4-
formyl-pyrazole and thiourea in glacial acetic acid with fused sodium acetate.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The
biological activities of synthesised compounds were compared with standard drugs.
N
N
CHO
ClCl
S
N
N R
R
O
+
NH2 NH2
S
H+
+
N N
ClNH
N
H
S
N
N
R
R
S
Cl
R = ArylType - (VI)
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYLIMINO-7,N-ARYL-
2-THIO-4-[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-
1,2,3,4-TETRAHYDRO-THIAZOLIDINO-[4,5-e]-PYRIMIDINES
[A] Preparation of 2-p-anisylimino-3-anisyl-5H-4-thiazolidinone
See, Part-II, Section-I (B)
[B] Preparation of 6-(p-anisylimino)-7,N-(p-anisyl)-2-thio-4-[1',N-phenyl-3'-
(2”,4”-dichlorophenyl)-pyrazol-4'-yl]-1,2,3,4 tetrahydro thiazolidino-[4,5-e]-
pyrimidine
A mixture of 2-(p-anisylimino)-3-(p-anisyl)-5H-4-thiazolidinone (3.28g, 0.01M)
1,N-phenyl-3-(2’,4’-dichlorophenyl)-4-formyl-pyrazole (3.16g, 0.01M) and thiourea
(0.76g, 0.01M) were taken in glacial acetic acid (20 ml) with fused sodium acetate(1.25g,
0.015M). The reaction mixture was refluxed for 12 hrs., cooled and poured into crushed
ice. The product was isolated and crystallised from methanol-DMF. Yield 70%, m.p.
225oC (C34H26Cl2N6O2S2, Found : C, 59.56`%; H, 3.82%; N, 12.26% Requires : C,
59.59%; H, 3.80%; N, 12.38%;).
TLC solvent system : Acetone : Benzene (2.5 : 7.5).
Similarly other pyrimidines were prepared. The physical data are recorded
in Table No. 6.
[C] Therapeutical activity of 6-Arylimino-7,N-aryl-2-thio-4-[1',N-phenyl-3'-
(2”,4”-dichlorophenyl)-pyrazol-4'-yl]-1,2,3,4-tetrahydro-thiazolidino-
(4,5-e)-pyrimidines
Antimicrobial testing was carried out as described in [A] Part-I, Section-I(D).
The zone of inhibition of the test solution are recorded in Graphical Chart No.6.
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IR SPECTRAL STUDY OF  6-(P-ANISYL)IMINO-7,N-(P-ANISYL)-2-THIO-4-
[1’ ,N-PHENYL-3’- (2” ,4”-DICHLOROPHENYL)-PYRAZOL-4’YL]-1 ,2 ,3 ,4 -
TETRAHYDROTHIAZOLIDINO-[4,5-E]-PYRIMIDINES.
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
N N
Cl
NH
N
H
S
N
N
S
H3CO
H3CO
Cl
 Observed
Alkane C-H str. (asym.) 2959 2975-2950 515
-CH3 C-H str. (sym.) 2841 2880-2860  “
C-H i.p.def. (asym.) 1424 1470-1435  “
Aromatic C-H str. 3089 3080-3030  ”
C=C str. 1559 1585-1480 516
C-H i.p. def. 1086 1125-1090   “
C-H o.o.p. def   836     835-810   “
Pyrazole C=N str. 1613 1630-1590 517
moiety C-N str. 1177 1230-1020   “
C-Cl str.  743    830-560 515
Ether C-S-C str. (asym.) 1254 1275-1200  “
C-S-C str. (sym.) 1026 1075-1020  “
Pyrimidine N-H str. 3414 3500-3350 518
     ring C=N str. 1613 1650-1550  ”
                                      (overlapped)
C=S str.  743 700-750  “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
 460.0
 522.7
 536.2
 568.0
 622.0
 686.6
 702.0
 743.5
 811.0
 836.1
 873.7
 964.3
 990.4
1026.1
1086.8
1177.5
1254.6
1306.7
1378.0
1424.3
1470.6
1496.7
1559.3
1592.1
1613.3
2331.8
2841.0
3089.8
3414.7
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 6-(p-ANISYL)IMINO-7,N-(p-ANISYL)-2-THIO-4-
[ 1 ’ , N - P H E N Y L - 3’-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4’YL]-1,2,3,4-
TETRAHYDROTHIAZOLIDINO-[4,5-E]-PYRIMIDINES.
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1.      3.82 6H singlet Ar-OCH3 +
Ar-OCH3       -
2.      6.91 4H singlet ArHgg’+Hjj’       -
3.      7.01 2H doublet ArHhh’ Jhg = 7.8
4.      7.36 4H multiplet Ar-Ha+Ar-He       -
                  +Ar-Hf+Ar-Hk
5.      7.42 2H doublet Ar-Hbb’ Jbc = 8.1
6.      7.51 2H doublet Ar-Hcc’ Jcb = 8.1
7.      7.53 1H triplet Ar-Hd Jde = 2.0
8.      7.75 2H doublet  Ar-Hii’ Jij = 7.8
9.      8.09 1H singlet Ar-Hx       -
N N
Cl
NH
N
H
S
N
N
S
H3CO
H3CO
Cl
a b
b'
c
c'
d
e
f
x
h
h'g
g'
i
i'
j
j'
k
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EXPANDED AROMATIC REGION
N N
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H
S
N
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Cl
a b
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H
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N
S
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CH3
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that the compounds bearing
R=4-tolyl and 3-chloro,4-fluorophenyl have displayed good activity against B.coccus.
The compounds bearing R=4-tolyl, 2-nitrophenyl and 3-chloro,4-fluorophenyl have shown
considerable activity against S.aureus.
In case of Gram negative bacterial strains all the compounds were inactive against
E.aerogenes except the compound bearing R=4-methoxyphenyl and 2-nitrophenyl. While
the compounds bearing R=4-methoxyphenyl, 4-chlorophenyl and 3,4-dichlorophenyl
showed significant activity against P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested
species. However, the compounds having R=4-fluorophenyl and 4-chlorophenyl
displayed highest activity against A.niger.
` The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared
with standard drug viz. greseofulvin.
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INTRODUCTION
Pyridine is also called azabenzene and azine, is a heterocyclic aromatic tertiary
amine characterized by six-membered ring structure composed of five carbon atoms
and a nitrogen atom which replaces one carbon-hydrogen unit in the benzene ring
(C6H5N).Most derivatives are prepared by manipulation of pyridine and its simple
homologues in a manner similar to chemistry of the benzenoid chemistry. However, the
simple pyridine compounds are prepared by the cyclization of aliphatic raw materials.
Pyridine compounds are found in nature, for example nicotine from tobacco,
ricinine from castor bean, alkaloids such as coniine, piperine and nicotine.Some pyridine
system is active in the metabolism in the body. pyridine can be parent compoumd of
target compounds such as insecticides, herbicides, medicines, vitamines, food flavoring,
explosive and disinfectants.
Among a wide range of pyridines, 3-cyanopyridines(I) acquired a special attention
due to their wide range of therapeutic activities.In our continuation of work in the
chemistry of pyridine nucleus, we have undertaken the synthesis of some 3-cyanopyridine
derivatives.
SYNTHETIC ASPECTS
Preparation of 3-cyanopyridines have been cited in literature197-202 with
different methods.
1.   Dao-Lin & Kimiaki203 have prepared 2-methoxy-3-cyanopyridine derivatives by the
condensation of chalcones with malononitrile in sodium methoxide.
N
CN
2. 2-Trihalomethyl 5-cyanopyridine have been synthesised byJason WB Cooke204.
3. Ege and co-workers prepared 2-amino-3-cyanopyridine  derivatives  using arylidene
malononitrile + lithium isopropyl amide and DMF dichloride205,206.
4. Feng Shi and co-workers207 have prepared 2-amino-3-cyanopyridine derivative
by the reaction of aromatic aldehyde, ketone, malononitriles and ammonium
acetate under microwave irradiation without solvent.
MECHANISM
EtO CF2X
O
NMe2
NC
Toluene
NH4OAC
DMF N CF2X
NC
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N R'
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NH2
N
NaOMe
N
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R
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The reaction proceeds through conjugated addition of active methylene
compounds to the α,β-unsaturated system as shown below.
THERAPEUTIC IMPORTANCE
Much research has been carried out with an aim to finding therapeutic values of
pyridine skeleton since their discovery. The pyridine derivatives are reported to exhibit
a wide variety of biological activity.
1. Antifungal208
2. Antiepileptic209
3. Antibacterial210
4. Anticonvulsant211
5. Analgesic212
6. Insecticidal213
7. Antisoriasis214
8. Antihypertensive215
S. Guru et al.216 have synthesized various cyanopyridyl derivatives (I) and
documented their multiple biological activities.The oxide activator bleaching activity of
cyanopyridine has been proved by Rees M.217. Oshida M.218 prepared
cyanopyridine derivatives which inhibit cerebral edema and delayed neuron death hence,
they are useful as cerebral edema inhibitors or cerebrovascular disorder remedies.
The insecticidal activity of cyanopyridines have been screened by Y. Sasaki219
et al..Aivars Krauze et. al.220 have synthesised 3-cyanopyridine derivatives & shown
their neurotropic and selective antiamesic activity  at dose of 0.05-0.5 mg/kg. This effect
was significantly higher that induced by Piracetam at 50 mg/kg. F. Manna et. al.221
O
N
NH2
R
N
(I)
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have prepared 3-cyano-pyridine derivatives as antiinflammatory, analgesic and antipyretic
agent.Some new 3-cyanopyridine derivatives synthesized by Hammama A. and
coworkers222 showed anticancer and anti HIV-I activity. Abdallah N. et al.223 have
synthesized and reported analgesic and antiinflammatory activity.
S. V. Roman et. al.224 have investigated 2-amino-3-cyanopyridine derivatives
and reported their biological activity.Abu and co-workers225 have described novel fused
cyanopyridines for the treatment of fungal infection.El-Taweel and co-workers226 have
described cyanopyridine derivatives (II) and showed their significant biological
activity.Pyachenko V. D. and co-workers227 have shown some cyanopyridines (III)
which are useful in treatment of retroviral disease.Hironori et. al.228 have prepared
cyanopyridines and screened for their large conductance calcium activiated potassium
channel opener activity.
Edwin B. Villhauer and co-worker229 have reported the first use of solid-phase
synthesis in the discovery of a new DPP-IV inhibitor class and a solution-phase synthesis
that is practical up to the multikilogram scale. One compound, NVP-DPP728 (IV), is
profiled as a potent, selective and shortacting DPP-IV inhibitor that has excellent oral
bioavailability and potent antihyperglycemic activity.
N
O
NH2NC
N
N
N
NH2
Se
        (II)      (III)
N NH
NH
O
N
CN
NC
(IV)
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Wu Wenxue et al.230 have synthesized cyanopyridines as histamine H3
antagonists.Moustafa M. A. et al.231 have prepared cyanopyridines as antibacterial
agents. Rosentreter Ulrich et al.232 have synthesized a new cyanopyridine as receptor
agonists in the treatment of  cancer disease , inflammation, neurodegenerative
disease(V).Fatma Goda & co-workers233 have synthesised 2-alkoxy pyridines (VII)
and studied their antimicrobial activity.
CONTRIBUTION FROM OUR LABORATORY
Akhil Bhatt and co-workers234 have synthesised cyanopyridines as potential
antimicrobial agents. R. C. Khunt et. al.235 have screened cyanopyridine derivatives
used as biologically active agents. Synthesis and antimicrobial activity of cyanopyridines
is shown by B. P. Kansagara et. al.236 J. R. Patel & co-workers237 have prepared
cyanopyridines bearing 2-chloro-6-bromoquinoline nucleus as potential anticancer agents.
Synthesis and biological evaluation of cyanopyridines is screened by Pankaj Patel
& co-workers238. Rajeev Doshi and co-workers239 have described some novel
cyanopyridines as a new class of potential antitubercular agents. Cyanopyridines have
been screened by A. V. Dobaria et. al.240 and showed their significant biological activity.
Ketan Hirpara & co-workers241 have discovered cyanopyridines as antitubercular agents (VII).
Recently,Gary T.  Wang and co-workers242 have synthesized of  o-
trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyl
N
CN
CNR2CH2S
NH2
O(CH2)n OR1
N
N
CH3
Ar
Ar
        (V)         (VI)
N
N
S
N
NH2
N
R
(VII)
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transferase(VIII). Foks H. and co-workers243  have synthesised cyanopyridine derivatives
and reported their antimicrobial activity. These compounds were tested in vitro for their
activity towards 25 strains of anaerobic and 25  strains  of aerobic bacteria. They showed
good activity towards the anaerobic bacteria.
In view of therapeutic activities shown by cyanopyridines, it was contemplated
to synthesize some new cyanopyridines in search of agents possessing higher biological
activity with least side effect have been described as under.
SECTION-I    : SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-
M E T H O X Y- 3 - C YA N O - 4 - [ 1 ' , N - P H E N Y L - 3 ' - (2” ,4” -
DICHLOROPHENYL)-PYRAZOL-4'-YL]-6-ARYL-PYRIDINES
SECTION-II    : SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-
A M I N O - 3 - C YA N O - 4 - [ 1 ' , N - P H E N Y L - 3 ' - ( 2 ” , 4 ” -
DICHLOROPHENYL)-PYRAZOL-4'-YL]-6- ARYL-PYRIDINES
N
O
N
N
NC
N
R1
R2
F3C
CN
CH3
(VIII)
110Cyanopyridines...
SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-METHOXY-3-CYANO-
4-[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL) PYRAZOL-4'-YL]-6-ARYL
PYRIDINES
The pyridine nucleus is found in a large number of commonly used drugs
which have diverse pharmacological activities. To achieving better drug potency
cyanopyridine derivatives of type (VII) have been prepared by the condensation of
chalcones of type (I) with malononitrile in the presence of sodium methoxide.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
R = ArylType - (VII)
N
N
O
R
Cl
Cl
CH2.(CN)2
N
N
Cl
N
R
H3CO
N
Cl
NaOMe
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-METHOXY-3-CYANO-
4-[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL) PYRAZOL-4'-YL]-6-ARYL
PYRIDINES
(A) Synthesis of 2,4-Dichlorophenylhydrazone143
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole144
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-Tolyl)-3-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-
pyrazol-4'-yl]-2-propen-1-one
See [A] Part-I, Section-I (C).
[D] Synthesis of 2-Methoxy-3-cyano-4-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-
pyrazol-4'-yl]-6-tolyl-pyridine
A mixture of 1-tolyl-3-(1',N-phenyl)-3'-(2”,4”-dichlorophenyl pyrazol-4'-yl)-2-
porpen-1-one (4.33g, 0.01M), malononitrile (0.66 g, 0.01 M) and sodium methoxide
(10 ml) (6.61g, 0.08M) dissolved in absoulte alcohol was refluxed for 10 hrs. in water
bath.  The reaction product was poured into ice, crude product was isolated, crystallised
from ethanol. Yield 70%, m.p. 250oC (C29H20Cl2N4O ; Found : C, 68.11%; H, 3.94%;
N, 10.96%; Requires : C, 68.13%; H, 3.93%; N, 11.21%).
TLC solvent system : Ethyl acetate : Hexane (2 : 8).
Similarly other cyanopyridines have been obtained. The physical data are
recorded in Table No. 7.
[E] Therapeutic activity of 2-Methoxy-3-cyano-4-[1',N-phenyl- 3'-(2”,4”-
dichlorophenyl)-pyrazol-4'-yl]-6-aryl-pyridines
Antimicrobial testing was carried out as described in Part-I, Section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No.7.
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IR SPECTRAL STUDY OF 2-METHOXY-3-CYANO-4-[1',N-PHENYL-3'-(2”,4”-
DICHLOROPHENYL) PYRAZOL-4'-YL]-6-(P-TOLYL) PYRIDINES
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
 Observed
Alkane C-H str. (asym.) 2943 2975-2950 515
-CH3 C-H str. (sym.) 2846 2880-2860   “
C-H i.p.def. (asym.) 1461 1470-1435   “
C-H o.o.p. def. (sym.) 1344 1390-1370   “
Aromatic C=H str. 3076 3080-3010 516
C=C str. 1500 1585-1480   “
C-H i.p. def. 1095 1125-1000   “
C-H o.o.p. def  825    835-810   “
Pyrazole C=N str. 1587 1630-1590 517
moiety C-N str. 1157 1230-1020   “
C-Cl str.  758    600-800 515
Ether C-O-C str. (asym.) 1242 1275-1200   “
C-O-C str. (sym.) 1037 1075-1020   “
Pyridine ring C≡N str. 2219 2240-2120 522
C=N str.. 1558 1650-1580   “
C=C str. 1500 1585-1480             “
                                    (overlapped)
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
20.0
40.0
60.0
80.0
100.0
%T
750.01000.01250.01500.01750.02000.03250.0
 684.7
 758.0
 825.5
 954.7
1037.6
1095.5
1157.2
1242.1
1265.2
1344.3
1371.3
1421.4
1461.9
1500.5
1558.4
1587.3
2219.9
2846.7
2943.2
3076.2
3423.4
N
N
Cl
NN
CH3
Cl
O
CH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 2-AMINO-3-CYANO-4-[1',N-PHENYL-3'-( 2 ” , 4 ” -
DICHLOROPHENYL) PYRAZOL-4'YL]-6-(p-TOLYL)-PYRIDINES
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 2.39 3H singlet Ar-CH3        -
2. 4.16 3H singlet Ar-OCH3        -
3. 6.96 1H singlet Ar-Hi        -
4. 7.22 2H doublet Ar-Hgg’    Jgh = 8.0
5. 7.40 2H multiplet Ar-Hae        -
6. 7.48 3H triplet Ar-Hbb’, Ar-Hf    Jbc = 7.5
7. 7.55 2H doublet Ar-Hcc’    Jcc’= 8.1
8. 7.79-7.81 2H doublet Ar-Hhh’    Jhg = 8.0
9. 8.66 1H singlet CHx        -
N
N
Cl
NN
CH3
Cl
O
CH3
a
b
b'
c
c'
d
e
f
g
g'
h
h'
i
114Cyanopyridines...
EXPANDED AROMATIC REGION
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R
      7a C6H5- 2215
7b 4-OCH3-C6H4- 2210
7c 4-CH3-C6H4- 2219
7d 4-F-C6H4- 2220
7e 4-Cl-C6H4- 2212
7f 4-Br-C6H4- 2214
7g 2-NO2-C6H4- 2219
7h 3-NO2-C6H4- 2220
7i 3-Cl,4-F-C6H3- 2222
7j 2,4-(Cl)2-C6H3- 2212
7k 3,4-(Cl)2-C6H3- 2218
7l 4-OCH3-C6H4- 2210
C≡N str.
IR SPECTRAL STUDY OF 2-METHOXY-3-CYANO-4-[1’,N-PHENYL-3’-(2”,4”-
DICHLOROPHENYL)-PYRAZOL-4’-YL]-6-ARYL-PYRIDINES
N
N
Cl
NN
CH3
Cl
O
CH3
a
b
b'
c
c'
d
e
f g
g'
h
h'
i
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O
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ZONE OF INHIBITION IN mm B.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data it has been concluded that all the compounds
were mildly active against Gram positive bacterial strains except R=phenyl,4-
hydroxyphenyl and 4-nitrophenyl which showed highest activity against B.coccus and
R=4-chlorophenyl and 3-nitrophenyly  which showed highest activity against S.aureus.
In case of Gram negative bacterial strains, the compounds bearing R= 4-tollyl
have exhibited significant activity against E.aerogenes. The compounds bearing R=4-
chlorophenyl and 4-hydroxyphenyl   have shown maximum activity against P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds were mildly active against A.niger. Maximum activity
was shown by the compounds bearing R=4-chlorophenyl and 4-fluorophenyl.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared
with standard drug viz. greseofulvin.
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SECTION - II
SYNTHESIS ANDTHERAPEUTIC EVALUATION OF 2-AMINO-3-CYANO-
4-[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL) PYRAZOL-4'YL]-6-ARYL-
PYRIDINES
In the past years, considerable evidence has been accumulated to demonstrate
the efficiency of cyanopyridines. To further assess the potential of such a class of
compounds cyanopyridine derivatives of type (VIII) have been synthesised by
condensation of malononitrile and ammonium acetate with 1-aryl-3-[1',N-phenyl-3'-
(2”,4”-dichlorophenyl)-pyrazole-4'-yl]-2-propen-1-ones.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
 R = ArylType - (VIII)
N
N
O
R
Cl
Cl
CH2.(CN)2
N
N
Cl
N
R
NH2
N
Cl
CH3COONH4
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-3-CYANO-4-
[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL) PYRAZOL-4'-YL]-6-ARYL
PYRIDINES
(A) Synthesis of 2,4-Dichlorophenylhydrazone143
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole144
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p -tolyl)-3-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-
pyrazol-4'-yl]-2-propen-1-one
See [A] Part-I, Section-I (C).
[D] Synthesis of 2-Amino-3-cyano-4-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-
pyrazol-4'-yl]-6-(p-anisyl)-pyridine
A mixture of 1-Anisyl-3-[1',N-phenyl-3'-(2”,4”-dichlorohenyl)-pyrazol-4'-
yl]-2-porpen-1-one (4.49 g, 0.01M), malononitrile (0.66 g, 0.01 M) and ammonium
acetate (6.61g, 0.08M) dissolved in absoulte alcohol was refluxed for 10 hrs. in
waterbath.The reaction product was poured into  crushed ice, crude product was
isolated, crystallised from ethanol. Yield 62%, m.p. 248oC (C28H19Cl2N5O ; Found
: C, 65.63%; H, 3.74%; N, 14.29%; Requires : C, 65.65%; H, 3.72%; N, 14.11%).
Similarly other cyanopyridines have been obtained. The physical data are
recorded in Table No.8.
[E] Antimicrobial activity of 2-Amino-3-cyano-4-[1',N-phenyl-3'-(2”,4”-
dichlorophenyl) pyrazole-4'-yl]-6-aryl-pyridines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No.8.
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IR SPECTRAL STUDY OF  2-AMINO-3-CYANO-4-[1' ,N-PHENYL-3'-(2”,4”-
DICHLOROPHENYL) PYRAZOL-4'YL]-6-(p-TOLYL)-PYRIDINES
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
 Observed
Alkane C-H str. (asym.) 2947 2975-2950 515
-CH3 C-H str. (sym.) 2862 2880-2860   “
C-H i.p.def. (asym.) 1458 1470-1435   “
C-H o.o.p. def. (sym.) 1369 1390-1370   “
Aromatic C-H str. 3070 3080-3010 516
C=C str. 1546 1585-1480   “
C-H i.p. def. 1095 1125-1000   “
C-H o.o.p. def   821    835-810   “
Pyrazole C=N str. 1581 1630-1590 517
moiety C-N str. 1153 1230-1020   “
C-Cl str.   744    600-800 515
Ether C-O-C str. (asym.) 1242 1275-1200   “
C-O-C str. (sym.) 1033 1075-1020   “
Pyridine ring C≡N str. 2218 2240-2120 522
C=N str.. 1581 1650-1580   “
                                       (overlapped)
N=H str. 3429 3450-3250   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 513.0
 617.2
 682.8
 744.5
 821.6
 887.2
 956.6
 987.5
1033.8
1095.5
1153.4
1242.1
1342.4
1369.4
1419.5
1458.1
1500.5
1546.8
1581.5
2218.0
2862.2
2947.0
3070.5
3429.2
N
N
Cl
NN
CH3
Cl
NH2
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 2-AMINO-3-CYANO-4-[1',N-PHENYL-3'-(2” ,4” -
DICHLOROPHENYL) PYRAZOL-4'YL]-6-(p-TOLYL)-PYRIDINES
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1.      3.87 3H  singlet Ar-OCH3         -
2.      4.15 2H  singlet NH2         -
3.      6.92 3H  triplet Ar-Hgg’, Ar-Hi    Jgf = 8.2
4.      7.40 2H  multiplet Ar-Ha,Ar-He         -
5.      7.48 2H  multiplet Ar-Hd,Ar-Hf         -
6.      7.55 2H  doublet Ar-Hbb’              Jbc = 8.2
   7.             7.65 2H  doublet Ar-Hcc’    Jcb = 8.2
8.      7.78 2H  doublet Ar-Hhh’              Jhg = 8.0
9.      8.65 1H  singlet CHx          -
N
N
Cl
NN
CH3
Cl
NH2
a
b
b'
c
c'
d
e
f g
g'
h
h'
i
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EXPANDED AROMATIC REGION
IR SPECTRAL STUDY OF 2-AMINO-3-CYANO-4-[1’,N-PHENYL-3’-(2”,4”-
DICHLOROPHENYL)-PYRAZOL-4’-YL]-6-ARYL-PYRIDINES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R
      8a C6H5- 2220
8b 4-OCH3-C6H4- 2215
8c 4-CH3-C6H4- 2218
8d 4-F-C6H4- 2230
8e 4-Cl-C6H4- 2219
8f 4-Br-C6H4- 2225
8g 2-NO2-C6H4- 2228
8h 3-NO2-C6H4- 2230
8i 3-Cl,4-F-C6H3- 2221
8j 2,4-(Cl)2-C6H3- 2217
8k 3,4-(Cl)2-C6H3- 2214
8l 4-OCH3-C6H4- 2226
C≡N str.
N
N
Cl
NN
CH3
Cl
NH2
a
b
b'
c
c'
d
e
f
g
g'
h
h'
i
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NN
Cl
N
N
CH3
Cl
NH2
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051015202530
ZONE OF INHIBITION IN mm B.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data it has been concluded that all the compounds
were mildly active against Gram positive bacterial strains except R=phenyl, 2-
hydroxyphenyland 2,4-dichlorophenyl which showed highest activity against B.coccus
and R=4-hydroxyphenyl and 4-nitroophenyl which showed highest activity against S.aureus.
In case of Gram negative bacterial strains, the compounds bearing R= 4-tolyl
have exhibited significant activity againstE. aerogenes. The compounds bearing
R=4-chlorophenyl and 4-hydroxyphenyl   have shown maximum activity against
P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds were mildly active against A.niger. Maximum activity
was shown by the compounds bearing R=4-chlorophenyl and 4-fluorophenyl.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared
with standard drug viz. greseofulvin.
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INTRODUCTION
Many naturally occuring and synthetic compounds containing the pyridone
scaffold possess interesting pharmacological and therapeutic activities.  Pyridones, with
a carbonyl group at position 2 have been subject of extensive study in the recent years.
Numerous reports have appeared in the literature which highlight their chemistry and
use. Among a wide range of pyridones, 3-cyanopyridones acquire a special attention
due to their wide range of biological activites in several therapeutic areas.
 Some 2-pyridones, which are pharmacologically important are as under: eg.
amrinone(II), ciclopirox(III) and methylprylon (IV).
SYNTHETIC ASPECTS
Different methods for preparation of cyanopyridones have been cited in the
literature are as follows :
1. Jacob M. Hoffman et. al.244 have synthesised 3-cyano-2-pyridone by the
raction  of various ketones with proponic acid and sodium methoxide in ethanol.
N
H
O
N
N
H
NH2
O
N
H
CH3
O
N
H
O
O
C2H5
C2H5
CH3
(II) (III) (IV)
(I)
O
CH3
R
OCH3
R
O
-Na+HCOOEt, NaoMe
EtOH / Et2O
N
H
CN
OCH3
R
Cyanoacetamide,
aq. piperidinium acetate
(V)   R = Alkyl
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2. W. Russel Bowman et. al.245 have synthesised cyanopyridone from 2,6-
dibromopyridine in presence of chlorotrimethylsilane and sodium iodide in
acetonitrile.
3. Rajul Jain et. al.246 have synthesised 3-cyano-2-pyridone by the reaction
of various enones with cyanoacetamide in presence of t-BuOK in DMSO under O2
atmosphere.
4. K. Follkers and S. A. Harris247have synthesised 3-cyano-2-pyridone by
the condensation of cyanoacetamide with 1,3-diketone or 3-ketoester.
MECHANISM
The addition reaction between ethylcyano acetate and α, β-unsaturated ketone give
cyanopyridone via Michael addition. Here, α, β-unsaturated compound is known as acceptor
and active methylene group containing compound known as addender. It involves
nucleophillic addition of carbanion to the C=C of the acceptor.
NBr Br N
H
O
N
(VI)
R1
O
R2 R3
+
NH2
O
N
t-BuOK
DMSO
O2
N
H
R1
R2
R3
N
O
R1, R2, R3= Alkyl (VII)
N
H
CH2OC2H5
N
O
CH3
O
NH2
N
+
O
CH3
H5C2OH2C
O
(VIII)
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THERAPEUTIC IMPORTANCE
Pyridone derivatives have been found to possess variety of therapeutic
activities as shown below.
1. Antiviral248
2. Pesticidal249
3. Angitensin II antagonist250
4. Herbicidal251
5. Anti HIV252
6. Anticancer253
7. Antimicrobial254
8. Cardiotonic255
Pednekar256 synthesised fused 2-pyridone derivatives (IX), (X) and (XI) as useful
heterocyclic moieties as they possess broad spectrum of biological activities such as antiviral,
CNS depressant, bactericidal and ulcer inhibitor.Moreover several co-workers have prepared
2-pyridones as S3 site of thrombin inhibitor257, herbicidal258, SH2 domain inhibitor259,
antimicrobial260, GABA-A receptor261 and antiinflammatory262. Upadhyay et. al.263  have
synthesised cyanopyridine derivatives which showed antifungal and antileishmanial activities.
R
O
R'
CNCH2COOC2H5
CH3COONH4
NH
O
N
R
R'
NH2
O
N
R
OH
R'
OC2H5
O
N
R
OH
R'
NH3
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Morishita Koji and co-workers264 have synthesised m-(2-oxo-1,2-dihydropyridyl)
urea derivatives (XII) possessing cholesterol acyltransferase (ACAT) inhibitory activity
and are useful for the treatment of hyperlipidemia and arteriosclerosis. Collins et. al.265
prepared heteroaryl pyridones as GABA a2/a3 ligands (XIII). Salman
266 has prepared
cyano pyridone derivatives as antibacterial & antifungal agent.
M. Potmesil & H. Pinedo267 have prepared 2-pyridone derivatives (XIV) as
antineoplastics, antitumor & antiviral agent. Mukhtar Hussain Khan and co-workers268 have
prepared 2-pyridone derivatives  (XV) which possess insecticidal and pesticidal activity.
M. G. Nizamuddin and co-workers269 have prepared cyanopyridone derivatives
(XVI) and reported their antifungal activity.Anticancer activity of 2-pyridones (XVII) have
N
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N
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been reported by Abou El-Fotooh and coworkers270.Haifeng Song & co-workers271 have
synthesised 3-cyano pyridones which are used as dyes and pigment.
E. Amer272 prepared-3-cyano-2-pyridone derivatives (XVIII) showing high
antimicrobial activity.Smith Terence273 has synthesised and reported pyridones (XIX)
as AMPA receptor antagonists for the treatment of demyelinating disorders and
neurodenerative diseases.Darcy Michael. G. et. al.274 have discovered some new
cyanopyridone derivatives which showed in vitro HCV NS5B inhibitory activity and
exhibited IC50 in the range of 0.0001 µM to 100 µM. Their pharmaceutical compositions
are useful for treating HCV infections.
Devdas B. et. al.275 have synthesised pyridone derivatives which are useful for
treating diseases and conditions caused or exacerbated by  unregulated P38 MAP kinase
and/or TNF activity, such as inflammation, ischemia, viral infections and autoimmune
diseases.Wang S. and co-workers276 have prepared 2-pyridone containing tricyclic
R
R1
O
NH
N
N
O
O N
R, R1 =Aryl
(XVI)
X
X
N
N
H
O
O
N
Et
X = F, Cl, Br
(XVII)
N
H
N
N
H
NN
O O
Ar Ar
N N
O
N
(XVIII) (XIX)
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alkaloid derivatives as potential inhibitors of tumor cell proliferation by regioselective
intramolecular N- and C-acylation of 2-pyridone.
Recently, Thomas C J et. al.277 have prepared 2-pyridone derivatives  as  antitumor
& antiviral agent.Nersesyan K. et. al.278 have investigated some new cyanopyridones
possessing genotoxic activity in marine cells and antitumor activity. Abdel-Galil E. Amar
et. al.279  have designed and synthesised cyanopyridone derivatives as antiinflammatory
agents.A novel series of pyridone inhibitors has been identified through pharmacophore
analysis as potent and selective VLA-4 integrin antagonists by Jason Witherington et. al.280
Jiang Q. and co-workers281 have identified a series of novel pyridones as kinase inhibitors
of ALK.
Thus the important role displayed by cyanopyridones for various physiological
activities prompted us to prepare a series of cyanopyridones having pyrazole nucleus
as parent molecule which has been described as under.
SECTION - I  :  SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-
      4-[1',N-PHENYL-3'-(2”,4”DICHLOROPHENYL)-PYRAZOL-4'-
      YL] -6-ARYL-1,2-DIHYDRO-2-PYRIDONES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-[1',N-
PHENYL-3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-6-ARYL-1,2-
DIHYDRO-2-PYRIDONES
Pyridone derivatives have remarkable therapeutic activity. Taking this into
consideration, we have undertaken the preparation of pyridone derivatives of type (IX)
by the condensation of chalcones of type-(I) with ethylcyanoacetate in the presence of
ammonium acetate as shown under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all the compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
N
N
Cl
R
O
Cl
CN-CH2-COOC2H5
CH3COONH4
N
N
Cl
NH
O
R
N
Cl
(IX)
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-CYANO-4-[1',N-
PHENYL-3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-6-ARYL-1,2-
DIHYDRO-2-PYRIDONES
(A) Synthesis of 2,4-dichlorophenylhydrazone143
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole144
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-anisyl)-3-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-
pyrazol-4'-yl]-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthesis of 3-cyano-4-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-pyrazol-4'-
yl]- 6-(p-anisyl)-1,2-dihydro-2-pyridone
 A mixture of 1-(p-anisyl)-3-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-pyrazol-4'-
yl]-2-propen-1-one (4.49 g, 0.01 M), ethylcyanoacetate (1.13 g, 0.01 M) and ammonium
acetate (6.16 g, 0.08 M) in absolute alcohol was refluxed for 12 hrs. The reaction
mixture was poured on to crushed ice and product was isolated and crystallised from
ethanol. Yield 68%, m.p. 240oC, (C28H18Cl2N4O2; Required : C, 65.51; H, 3.53;
N, 10.91;  Found : C, 65.53; H, 3.50; N, 11.13%).
TLC solvent system : Acetone : Benzene (1.5 : 8.5).
Similarly other substituted pyridones have been prepared. The physical
data are recorded in Table No. 9.
(E) Antimicrobial activity of 3-cyano-4-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-
pyrazol-4'-yl]-6-aryl-1,2-dihydro-2-pyridones
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 9.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-CYANO-4-(1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL)-
PYRAZOL-4'-YL)-6-(p-METHOXYPHENYL)-1,2-DIHYDRO-2-PYRIDONE
 Observed
Alkane C-H str. (asym.) 2918 2975-2950 515
-CH3 C-H str. (sym.) 2850 2880-2860   “
C-H i.p.def. (asym.) 1436 1470-1435   “
C-H o.o.p. def. (sym.) 1344 1390-1370   “
Aromatic C=C str. 1560 1585-1480 516
C-H i.p. def. 1095 1125-1090   “
C-H o.o.p. def  821    835-810   “
Pyrazole C=N str. 1598 1630-1590 517
moiety C-N str. 1234 1230-1020   “
C-Cl str.  752                 830-560 515
Ether C-O-C str. (sym.) 1062 1075-1020   “
Pyridone ring C≡N str. 2225 2240-2120 517
C=O str. 1637 1760-1655 516
N-H str. 3404 3450-3250 517
N-H def. 1560 1650-1580   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 455.2
 565.1
 688.5
 738.7
 752.2
 821.6
 958.6
1012.6
1062.7
1095.5
1234.4
1294.1
1344.3
1382.9
1436.9
1504.4
1560.3
1598.9
1637.5
2225.72850.6
2918.1
3404.1
N
N
Cl
NH
O
N
O
CH3
Cl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 3-CYANO-4-(1',N-PHENYL-3'-(2”,4”-DICHLORO-
PHENYL)-9-PYRAZOL-4'-YL)-6-(p-ANISYL)-1,2-DIHYDRO-2-PYRIDONE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1.   3.87 3H singlet Ar-OCH3          -
2.   6.91 3H triplet Ar-Hgg’, Ar-Hi    Jgh = 8.7
3.   7.12 2H doublet Ar-Hbb’    Jbc = 8.7
4.   7.53 2H triplet Ar-Hae          -
5.   7.60 2H multiplet Ar-Hf,Ar-Hd          -
6.   7.73 2H doublet Ar-Hcc’   Jcb = 8.8
7.   7.78 2H doublet Ar-Hhh’   Jhg = 8.7
   8.   8.37 1H singlet CHx         -
N
N
Cl
NH
O
N
O
CH3
Cl
a
b c
d
e
x
i
b' c'
g
g'
h
h'
f
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EXPANDED AROMATIC REGION
I R  S P E C T R A L  S T U D Y  O F  3 - C YA N O - 4 - ( 1 ' , N - P H E N Y L - 3 ' - ( 2 ” , 4 ” -
DICHLOROPHENYL-PYRAZOL-4'-YL)-6-ARYL-1,2-DIHYDRO-2-PYRIDONES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R    C=O str.
      4a C6H5- 1650 2217
4b 4-OCH3-C6H4- 1637 2225
4c 4-CH3-C6H4- 1635 2219
4d 4-Cl-C6H4- 1646 2224
4e 4-F-C6H4- 1654 2218
4f 4-Br-C6H4- 1652 2214
4g 4-OH-C6H4- 1639 2219
4h 2-OH-C6H4- 1645 2212
4i 4-NO2-C6H4- 1640 2220
4j 3-NO2-C6H4- 1642 2214
4k 2,4-di-Cl-C6H3- 1653 2210
4l 4-NH2-C6H4- 1647 2218
C≡N str.
N
N
Cl
NH
O
N
O
CH3
Cl
a
b c
d
e
x
i
b' c'
f
g
g'
h
h'
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data it has been concluded that all the compounds
were mildly active against Gram positive bacterial strains except R=4-tolyl, 4-
bromophenyland 4-nitrophenyl which showed highest activity against B.coccus and R=4-
fluorophenyl,2-hydroxy and 2,4-dichlorophenyl which showed highest activity against S.aureus.
In case of Gram negative bacterial strains, the compounds bearing R= 4-
methoxyphenyl and 4-hydroxyphenyl have exhibited significant activity against Aerogenes.
The compounds bearing R=phenyl and 2-hydroxyphenyl   have shown maximum activity
against Pseudomonas.
ANTIFUNGAL ACTIVITY
All the compounds were mildly active against A.niger. Maximum activity
was shown by the compounds bearing R=4-methoxyphenyl and 3-nitrophenyl.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared
with standard drug viz. greseofulvin.

147Isoxazoles...
INTRODUCTION
Isoxazoles are a class of heterocyclic compounds having remarkable number of
applications and have been demonstrated to be very versatile building blocks in organic
synthesis.
The key feature of these heterocycles is that they possess the typical properties
of an aromatic system but contain a weak nitrogen-oxygen bond, which under certain
reaction conditions, particularly in reducing or basic conditions, is a potential site of ring
cleavage. Thus, isoxazoles are very useful intermediates  since the ring system stability
allows the manipulation of substituents to give functionally complex derivatives, yet it is
easily cleaved when necessary. Consequently, isoxazole have become an important
synthetic tool.
In 1888, Claisen first suggested an isoxazole (I), a product from reaction of 1,3-
diketone with hydroxylamine282. Subsequently a solid foundation for the chemistry of
isoxazole was laid down by Claisen and his students. Quelico in 1964, made the next
important contribution to the chemistry of isoxazole, he begun to study the formation of
isoxazole from nitrile N-oxide and unsaturated compounds283.
SYNTHETIC ASPECTS
The construction of isoxazole ring was carried out by the reaction of hydroxylamine
hydrochloride with α,β-unsaturated carbonyl compounds, which results in an oxime,
which later on undergo cyclisation.
Various methods for the synthesis of isoxazoles have been cited in the literature
are described as under.
1. By the reaction of alkenes or alkynes with ammonium cerium  nitrate in acetone
or   acetophenone under reflux gave corresponding isoxazole derivative284.
O
N
(I)
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2. Four component coupling of a terminal alkyne, hydroxylamine, carbon monoxide
and an aryl iodide furnishes isoxazole derivatives in the presence of a palladium
catalyst285.
3. By the reaction of nitrile oxide, TEA and POCl3with ethyl-3-perfluoroalkyl-3-
pyrolidine-acrylates286.
4. By the reaction of nitroalkanes with alkynes using microwave irradiation, using 4-
(4,6dimethoxy[1,3,5]triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) and
DMAP as catalyst287.
R1
CH2
CAN
Acetone
or
Acetophenone
NO
R1
O
R2
CAN
Acetone
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Acetophenone
NO
R3
O
R2
R3 N
(II)
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O
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CH3
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RCH2NO2
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R
O
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5. Jesse P. Waldo and Richard C. Larock288  have sythesised isoxazolederivatives
via  electrophilic cyclisation.
MECHANISM
Here the reaction proceeds via the formation of an oxime, which under goes
cyclisation in buffer media. Reaction take place between hydroxylamine and chalcone.
THERAPEUTIC IMPORTANCE
Isoxazole and its derivatives are shown to possess important biological and
pharmaceutical activites. Isoxazole motifs in drug candidates with good pharmacological
activities are listed below.
R1
R2
O
NH2OMe.HCl
R1
R2
N
OMe
E-X
O
N
R1
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E
E-X = I2, ICl, Br2, PhSeBr
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NO
S OO
NH2
CH3
Valdicoxib
    [Cox-2 inhibitor drug]
CF3
NH
O
N
O
CH3
       Leflunomide
[Antiinflammatory agent]
NH2 S
O
O
NH
O
N
CH3
CH3
Sulfamethoxazole
         [Antibacterial agent]
O
N
Cl H
NH2
COOH
 Acivicin
          [Antitumor]
S
N
CH3
O
NH
N O
CH3
OH
Isoxicam
    [Antiinflammatory]
The extensive use of  isoxazole derivatives  have been established in medicine
due to its variety of therapeutic activity shown as under.
1.  Fungicidal289,290
2.  Anticholestermic291
3. Hypoglycemic292
4. Antileukemic293
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5. Analgesic294
6. Anticonvulsant295,296
7. Antipyretic297
8. Antiinflammatory298-301
9. Nematocidal302
10. Muscle Relaxant303,304
11. Antitumor305
12. Anthelmintics306
13. Antiviral307
14. Antibacterial308-310
15. Antidiabetic311
Ulf Madsen et.al.312 have demonstrated isoxazole derivatives of type (VII) as
potent and selective ampa receptor antagonist.Aicher et. al.313 cited some isoxazole
derivatives possessing hypoglycemic activity. R. Ulrich et. al.314 have synthesised
isoxazole derivatives and reported their adrenergic antagonist activity.
Mauro Mazzei et.al315 have descovered isoxazole derivatives and reported them
as potential antiinflammatory agent.Nanteymet P. G. et. al.316 have discovered a non
peptidic isoxazole derivative  reported as antagonist of the human platelet thrombin
receptor (PAR1).Yoon-Suk and Byeang Hyean Kim317 have designed and synthesised
isoxazole derivatives(VIII) and reported as antivitral agent.
Daniele Simoni and Manlio Tolomeo318 have designed a novel g1 phase targetting
isoxazole derivative (IX) which is structurally related to arotinoids, was found to possess
interesting apoptotic activity.Andres J. I.et.al.319 have discovered a new series of
N
O
CH3
CH3
CH3
O
CH3
O
NH2
O
OH
ON
N NNH
H
BOC
OH
O
Bz
R'
R
R = CH2 C6H5
R' = CH3(VIII)(VII)
centrally active tricyclic isoxazoles combining serotinin (5-HT)-reuptake inhibition with
alpha(2)-adreno-ceptor blocking activity which is described as potential antidepressant.
Robert Sammelson et. al.320 have synthesised isoxazole derivatives(X) as a novel
class of activators for chloride conductance in the cystic fibrosis transmembrane
conductance regulatorn  protein.Patrizia Cali et. al.321 have synthesised & reported
isoxazoles (XI) as peptide deformylase inhibitors and potential antibacterial agent.
Bo Lui et. al.322 have discovered novel isoxazole carboxamides as growth hormone
secretagogue receptor (GHS-R) antagonists.Bente Frolund et. al.323 have reported
tetrazolyl isoxazole amino acids as ionotropic glutamate receptor antagonists.Bryan H.
Norman et. al.324 have reported cyclohexyl-linked tricyclic isoxazoles as potent and
selective modulators of the multidrug resistance protein (MRP1)(IX).
Cis form(IX)
R= Alkyl/Aryl
N
O
O
R4
R3R1
R2
R1,R2= Alkyl/Aryl
R3,R4= Alkyl
  (X)               (XI)
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CH3 CH3
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O
N
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O
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Cl
O
NHO
Ph
(IX)
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CONTRIBUTION FROM OUR LABORATORY
V. B. Patel and co-workers325 have prepared isoxazoles bearing sulphonamide
moiety and reported their antimicrobial activity. R. C. Khunt, A. R. Parikh and co-
workers326 have prepared isoxazole derivatives which possess antimicrobial  activity.
Rajeev Doshi & co-workers327 have discovered isoxazoles as a new class of potential
antitubercular agents. Ketan Hirpara et. al.328 have synthesised isoxazoles as antitu-
bercular agents. A. V. Dobaria et. al.329 have described the isoxazole derivatives and
their use as antimicrobial agents. B. P. Kansagar et. al.330 have demonstrated various
isoxazole and tested their antimicrobial activity.
Recently, Jie-Fei Cheng et. al.331 have synthesised isoxazole derivatives and
reported as MCD inhibitors.K. R. Scott and co-workers332 have demonstrated
isoxazoles(X) as anticonvulsant agents.Stefano Chimichi et.al.333 have documented
isoxazoles derivatives(XI) possessing antiproliferative activity. Wiles J. A. and co-workers334
have prepared des fluoroisothiazolo pyridone derivatives which exhibited antibacterial
activity and inhibitory activities against DNA gyrase and topoisomerase IV.
With a view to getting better therapeutic value, it was contemplated to
synthesise isoxazole derivatives incorporating pyrazole as parent molecule, to enhance
the overall activity of resulting compounds which have been described as under.
SECTION - I  :  SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL-
    5-[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-
    4'- YL]- ISOXAZOLES
153
N N
O
CH3
CH3 O
H
N
H
O
N
O
OH
(X)     (XI)
Isoxazoles...
154Isoxazoles...
SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL-5-[1',N-
PHENYL-3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-ISOXAZOLES
With a view to achieving better drug potency isoxazole derivatives of type (X)
have been prepared by the condesation of chalcones of type (I) with  hydroxylamine
hydrochloride in the presence of sodium acetate in glacial  acetic acid. The chalcones
were synthesised by the condensation of 1,N-phenyl -3-(2’,4’-dichlorophenyl)-4-formyl
pyrazole with various aromatic ketones.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
N
N
Cl
R
O
Cl
NH2OH.HCl
CH3COONa
N
N
O
N
R
Cl Cl
Type (X)    R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-(1' ,N-
PHENYL-3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL)-ISOXAZOLES
(A) Synthesis of 2,4-dichlorophenylhydrazone143
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole144
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-anisyl)-3-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-pyrazol-
4'-yl]-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthesis of 3-(p-anisyl)-5-[1',N-phenyl-3'-(2”,4”-dichlorophenyl)-
pyrazol-4'-yl]-isoxazole
A solution of anhydrous sodium acetate (1.46g, 0.02 M) in a minimum amount
of hot acetic acid was added to a solution of hydroxylamine hydrochloride (1.4 g, 0.02
M) in ethanol (20 ml). This solution was added to a solution of 1-(p-anisyl)-3-[1',N-
phenyl-3'-(2”,4”dichlorophenyl)-pyrazol-4'-yl]-2-propen-1-one (4.49 g, 0.01 M) in
ethanol (25 ml). The mixture was heated under reflux on waterbath for 12 hrs. The product
was isolated and recrystallised from ethanol.  Yield 70%, m.p. 185oC (C25H19Cl2N3O2;
Required : C, 64.95; H, 3.71; N, 9.09;  Found : C, 64.93; H, 3.73; N, 9.32%).
TLC solvent system : Acetone : Benzene (2.5 : 7.5).
Similarly other substituted isoxazoles have been prepared. The physical
data are recorded in Table No. 10.
(E) Antimicrobial activity of 3-aryl-5-[1',N-phenyl-3'-(2”,4”- dichlorophenyl)-
pyrazol-4'-yl]-isoxazoles
Antimicrobial testing was carried out as described in [a] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 10.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-(P-ANISYL)-5-[1',N-PHENYL-3'-(2”,4”-DICHLORO
PHENYL)-PYRAZOL-4'-YL]-ISOXAZOLE
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 447.5
 507.2
 688.5
 752.2
 806.2
 829.3
 867.9
 904.6
 958.6
 997.1
1029.9
1058.8
1101.3
1174.6
1220.9
1249.8
1303.8
1353.9
1382.9
1436.9
1498.6
1558.4
1596.9
2835.2
2931.6
3004.9
3060.8
3336.6
 Observed
Alkane C-H str. (asym.) 2931 2975-2950 515
-CH3 C-H str. (sym.) 2835 2880-2860   “
C-H i.p.def. (asym.) 1436 1470-1435   “
C-H o.o.p. def. (sym.) 1382 1390-1370   “
Aromatic C-H str. 3060 3080-3030   “
C=C str. 1558 1585-1480 516
C-H i.p. def. 1101 1125-1090   “
C-H o.o.p. def  829    835-810   “
Pyrazole C=N str. 1596 1630-1590 517
moiety C-N str. 1174 1230-1020   “
C-Cl str.  752    830-560             “
Ether C-O-C str. (asym.) 1249 1275-1200 515
C-O-C str. (sym.) 1058 1075-1020   “
Isoxazole C=C str. 1558 1580-1550   “
                                      (overlapped)
C=N str. 1498 1470-1460   “
N-O str.  806    850-800   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N
O
N
Cl
OCH3
Cl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 3- ( P - ANISYL) -5- [1 ' ,N-PHENYL-3' - (2” ,4”-
DICHLOROPHENYL)-PYRAZOL-4'-YL]-ISOXAZOLE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1.    3.76 3H singlet Ar-OCH3         -
2.    6.91 2H doublet Ar-Hgg’   Jgh = 8.8
   3.    7.22 2H doublet Ar-bb’   Jbc = 8.7
4.    7.28 1H singlet Ar-Hi         -
5.    7.39 2H multiplet Ar-Ha+Ar-He         -
6.    7.52 4H multiplet Ar-Hf+Ar-Hd+         -
Ar-Hcc’    Jcb = 7.9
7.    7.83 2H doublet Ar-Hhh’   Jhg = 8.8
9.    8.21 1H singlet CHx         -
N
N
O
N
Cl Cl
O
CH3
a
b
c
d
e
h gxb' c'
f
h' g'
i
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EXPANDED AROMATIC REGION
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that all the isoxazole
derivatives (V) markedly inhibit the growth of Gram positive bacteria and also
Gram negative bacteria.
All compounds showed moderate activity against Gram positive bacteria.
However, maximum activity was observed in compounds bearing R=4-fluorophenyl,
and 4-hydroxyphenyl against B.coccus whereas R= 2-hydroxyphenyl against S.aureus.
In case of Gram negative bacterial strains, the maximum activity was
displayed by the compounds bearing R=4-fluorophenyl and 2-hydroxy phenyl against
Aerogenes. While the compounds with R= 4-bromophenyl, 4-hydroxyphenyl and
4-methoxyphenyl have shown considerable activity against Pseudomonas.
ANTIFUNGAL ACTIVITY
All compounds exhibited mild activity against A.niger except compound bearing
R=4-fluorophenyl and 2,4-dichlorophenyl which showed good activity against A.niger.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared
with standard drug viz. greseofulvin.

163Imidazolinones...
INTRODUCTION
Imidazolinone, a five membered heterocycle having 2-nitrogen atoms at the 1
and 3-positions and C=O group at following positions : 2-oxo-imidazoline (I), 4-oxo-
imidazoline (II), 5-oxo-imidazoline (III).
The discovery of the 2-substituted-5-imidazolines dates back to the year 1888,
when A. W. Hoffman335 for the first time discovered 5-oxo-imidazoline by heating N'-
diacetylethylene diamine in a stream of dry hydrogen chloride. Moreover the same
compound was prepared by A. Ladenburg336 by the fusion of two equivalents of sodium
acetate with one equivalent of ethylene diamine dihydrochloride.
SYNTHETIC ASPECTS
Various methods have been reported for the synthesis of imidazolinones in
literature337.
1. Aminolysis of oxazolone with amine leads to the formation of imidazolinones338.
2. Jean Michel Lerestif et. al.339 have synthesised imidazolinone from α
−
aminoester.
3. Said Oumouch et.al.340 have synthesised imidazolinone by the reaction of
benzamidine with ethylchloroacetate and an aromatic aldehyde.
(III)(II)(I)
N
N
H
O
N
N
H
O
N
N
H
O
R1
O
CH3
N O
OR2
CH3
N R4
R3+
70
N
N
O
R3
R1
R4
C
R1,R2 = Alkyl (IV)R3,R4 = Alkyl or Aryl
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4.   Rao Y. S. and Filler R.341 have prepared 2-arylimidazolin-5-ones by the
treatment of an oxazolone intermediate with an aryl/alkylamine.
5. A. Saxena et. al.342 have synthesized new imidazolinones in dry pyridine.
MECHANISM
Azlactone reacts with variety of compounds such as water, alcohols, amines and
hydrogen halides. Amides of α-acylamino acryclic acids obtained from the condensation
of azalactone and primary amines can be converted into imidazolinones as shown under.
The ring closure can be affected under a variety of conditions. Substituted anilides have
been converted to imidazolinone derivatives by the action of POCl3.
O
N O
Ar
R
N
N O
R
Ar R'
R' NH2
O
N
O
Ar
Cl
NHNH2
O
Dry Pyridine
ONH
Cl
N
N
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(VII)
NH2
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4-MeOC6H5CHO+
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THERAPEUTIC IMPORTANCE
Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various
imidazolinone derivatives which have been used as adrenergic stimulants and Tolazoline
and Phenotolamine as adrenergic blocking agents. Various imidazolinones are known to
exhibit a broad spectrum of biological activities such as,
1.   Antiinflammatory343-345
2.   Antidiabatic346
3.   Antiparkinsonian347,348
4.   Antihistaminic349
5.   Antiviral350
6.   Anticonvulsant351,352
7.   Insecticidal353
8.   Antitubercular354
9.   Thrombin inhibitor355
10. Glucagon antagonists356
11. Antimicrobial357
12. Hypertensive358
13. A nticancer359,360
14. Potent CNS depressant361,362
15. Bactericidal363,364
16. Fungicidal365,366
17. Anthelmintic367
18. Local anaethetic368
19. Antiarrhythmic369
N
O
O
X
R
R'-NH2 NH
X
R
O
NHO
R'
POCl3
N
N O
R
R'X
R’-NH2, DryC5H5N/Abs. C2H5OH, K2CO3
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Mimi L. Quan et.al.370 have synthesised iidazolinone derivatives (VIII) as
nonpeptide angiotensin II receptor antagonist.Christopher Geoffrey et. al.371 have
synthesised imidazolinones and reported their antifungal activities.Rama Sharma and co-
workers372 have formulated 5-oxo-imidazolines possessing potential antimicrobial
activity. Yong In Kuk et. al.373 have investigated some imidazolinones and reported
them an herbicides and Acetolactuse sunthease (ALS) inhibitor.
Yehudit Zohar et.al.374 have discovered some imidazolinones derivatives and
studied their antituberculosis activity. Siew Siew Pang et. al.375 have discovered some
new imidazolinone derivatives and reported their herbicidal activityKeun-Jin Oh et. al.376
have investigated some imidazolinone derivatives abolished the enzymatic activity as
well as the binding affinity for the cofactor FAD (Flavin adenine dinucleotide).
Prisinzano T. et. al.377 have synthesised & reported imidazoline derivatives as
human 5-HT(1D) serotonin receptor ligands. Zhong Jin378 has found imizoline derivatives
(IX) as cytoxic towards several tumor cell lines.
Moutevelis-Minakakis P. et. al.379 have synthesised imidazolines as
antihypertensive agent. Katarzyna Kiee-Knonowicz et. al.380 have discovered
N
N
OR1
R2
R3
A
 (VIII)       R1,R2,R3= Alkyl
       A= Tetrazole
NH
N
N
NH3CO
OCH3
OCH3N
O CH3
O
(IX)
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imidazolinones  as antimicrobial agents. Solankee A.381 have synthesised some
imidazolinone derivatives (X) and screened for their anticancer activity. Irene M. L. et.
al.382 have investigated some imidazolinone derivatives possessing antireteroviral activity.
Lee Jin Ho et. al.383 have formulated imidazolinones and tested for their anticancer activity.
Ozaki Satoshi et. al.384 have reported imidazolinones useful as analgesic,
antagonists against tolerance to narcotic analgesics typified by morphine, agents for the
treatment of obesity and drugs for ameliorating brain function. Jean M. R. et. al.385
have discovered imidazolinones and tested as antileishmanial agents.Kallurava B. et.
al.386 have reported antibacterial, antiinflammatory and analgesic activity of 5-oxo-
imidazoline derivatives.
CONTRIBUTION FROM OUR LABORATORY
 Dr. H. H. Parekh et. al.387 suggested imidazolinones as a antitubercular,
anticancer (XIII) agents.
H. H. Parekh and co-workers388 have synthesised 5-oxo-imidazolines as novel
bioactive compounds derived from benzimidazole. P. H. Patel and co-workers389 have
discovered imidazolines bearing 2-amino-thiazole moiety as antimicrobial agents.
N
N
N
N
O
Ph
CH3CH3
Ph
OAr
N
NH
N
O CH3
COOHR
CH3
CH3
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R. C. Khunt, N. J. Datta and A. R. Parikh390 have reported 5-oxo-imidazolines
as biologically active agents. Hasmukh Kanjaria and co-workers391 have described
imidazolinones as potential antimicrobial agents. Satyen P. Patel and co-workers392
have synthesised imidazolines as biologically active agents.
Joshi H. et. al.393 have synthesised imidazolinones as potent anticonvulsant
agents. Parikh et. al.394 have reported 4-(4’-arylidene-2’-phenyl-5’-oxo-imidazolin-
1’-yl)-benzophenone and screened for their antimicrobial activity.
Recently, Aleksey Vasiliev et. al.395 and C. Alister and co-workers396 have
synthesised imidazolinone derivatives (XI) and reported their herbicidal activity.Gupta
J. K.et.al.397 and E. Jayachandran et. al.398 have synthesised imidazolinones
derivatives(XII) and documented as antimicrobial agents.Imidazolinone derivatives as
acetohydroxyacid  synthase (AHAS) inhibitors hve been suggested by Tan S. and
co-workers399.
With a view to getting better therapeutic agent, it was contemplated to synthesize
imidazolinones to enhance the overall activity of resulting compounds which have been
described as under.
SECTION I     : SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,N-
A R Y L -  2 - P H E N Y L - 4 - [ 1 ’ , N - P H E N Y L - 3 ’ - ( 2 ” , 4 ” -
DICHLOROPHENYL)-4’-PYRAZOLYLMETHINE]-
IMIDAZOLIN- 5-ONES
N
N
NH NH
S
OO
CH3
O
CH3
Ar
(XIII)
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,N-ARYL-2-PHENYL-
4-(1’,N-PHENYL-3’-(2”,4”-DIHLOROPHENYL) -4’-PYRAZOLYLMETHINE)-
IMIDAZOLIN-5-ONES
Imidazol inone  der iva t ives  possess  var ie t ies  of  b io logica l  and
pharmacological properties. Here, we report the synthesis of some new 5-oxo-
imidazolines of type (XI). The strategy employed for the synthesis of desired compounds
involved the condensation of azalactones with different aromatic amines shown as under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
N
N
Cl
O
N
O
Cl
R-NH2
Pyridine
N
N
Cl
N
N
O
Cl
R
Type (XI)              R = Aryl
REACTION SCHEME
Type - (XI)
N
N
Cl
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Cl
CO
NH COOH+
(CH3CO)2O
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,N-ARYL-2-PHENYL-
4-[1’,N-PHENYL-3’-(2”,4”-DICHLOROPHENYL)-4’-PYRAZOLYLMETHINE]-
IMIDAZOLIN-5-ONES
(A) Synthesis of 1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole144
See [A] Part-I, Section-I (B).
(B) Synthesis of 2-Phenyl-4-[1' ,N-phenyl-3'-(2”,4”-dichlorophenyl)-
4'-pyrazolylmethino]-oxazolin-5-one
A mixture of 1,N-phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole (3.17
g,0.01M), acetic anhydride (7.6ml, 0.075M), sodium acetate (2.0 g, 0.025M) and
hippuric acid (4.4g, 0.025M) was heated on waterbath for 4 hrs. Resulting mass was
poured onto crushed ice, filtered, washed with hot water and crystallised from
ethanol. Yield 76%, m.p. 152oC, (C25H15Cl2N3O2 : Required C : 65.23; H : 3.28; N: 9.13;
Found C : 63.25; H : 3.30; N : 9.11%).
TLC solvent system : Ethyl acetate : Hexane (2.5 : 7.5)
(C)  S y n t h e s i s  o f  1 , N - p - to l y l - 2 - p h e n y l - 4 - [ 1 ' , N - p h e n y l - 3 ' - ( 2 ” , 4 ” -
 dichlorophenyl)- 4'-pyrazolylmethino]-imidazolin-5-one
A mixture of 2-Phenyl-4-[1' ,N-phenyl-3'-(2’ ,4”-d ichlorophenyl-4'-
pyrazolylmethino]-oxazolin-5-one (4.35 g, 0.01M) and p-toludine (1.07g, 0.01M) in
dry pyridine (20 ml) was refluxed for 12 hrs. Resulting mass was poured on to crushed
ice and neutralised with HCl, filtered and crystallised from DMF. Yield,  65%, m.p.
216oC (C32H22Cl2N4O : Required C: 69.95; H: 4.04; N: 10.20; Found : C: 69.97; H:
4.01; N: 10.41%).TCL solvent system : Acetone : Benzene (1.8 : 8.2).
Similarly other imidazolin-5-ones have been prepared. The physical data
are recorded in Table No. 11.
(D)  Antimicrobial activity of 1,N-aryl-2-phenyl-4-[1’,N-phenyl-3’-(2”,4”-dichloro
 phenyl)-4’-pyrazolylmethine]- imidazolin-5-ones
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 11.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1,N-P-TOLYL-2-PHENYL-4-[1',N-PHENYL-3’-(2”,4”-
DICHLOROPHENYL)-4'-PYRAZOLYLMETHINO]-IMIDAZOLIN-5-ONE
 Observed
Alkane C-H str. (asym.) 2923 2975-2950 515
-CH3 C-H str. (sym.) 2831 2880-2860   “
C-H i.p.def. (asym.) 1436 1470-1435   “
C-H o.o.p. def. (sym.) 1361              1390-1370   “
Aromatic C-H str. 3053 3080-3030   “
C=C str. 1510 1585-1480 516
C-H i.p. def. 1107 1125-1090   “
C-H o.o.p. def  821    835-810   “
Pyrazole C=N str. 1591 1630-1590 517
moiety C-N str. 1168 1230-1020   “
C-Cl str.  781    830-560 515
Ether C-O-C str. (asym.) 1251 1275-1200   “
C-O-C str. (sym.) 1072 1075-1020   “
Imidazolinone C=O str. 1718 1770-1655   “
ring C=N str. 1612 1650-1550   “
C-N str. 1251 1260-1220   “
                                   (overlapped)
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N
Cl
N
N O
CH3
Cl
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 455.2
 476.4
 505.3
 588.2
 705.9
 732.9
 781.1
 821.6
 866.0
 945.1
 987.5
1031.8
1072.3
1107.1
1168.8
1251.7
1361.7
1409.9
1436.9
1479.3
1510.2
1548.7
1591.2
1612.4
1718.5
2831.3
2923.9
3053.1
3390.6
173Imidazolinones...
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 1,N-P-TOLYL-2-PHENYL-4-[1',N-PHENYL-(2”,4”-
DICHLOROPHENYL)-4'-PYRAZOLYLMETHINO]-IMIDAZOLIN-5-ONE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
 1.       2.41 3H  singlet          Ar-CH3            -
 2.       7.09 2H  doublet         Ar-Hhh’      Jhg = 8.4
 3.       7.17 1H  singlet          Ar-Hl            -
 4.       7.31 3H  multiplet       Ar-Ha+Ar-Hf+
                    Ar-He            -
 5.       7.37 4H  multiplet       Ar-Hbb’+Ar-Hcc’          -
 6.       7.46 5H  multiplet       Ar-Hii+Ar-Hjj
                                                                           Ar-Hk                          -
 7.       7.57 1H  singlet          Ar-Hd                Jde = 2.1
    8.       7.85 2H  doublet         Ar-Hgg’      Jgh = 8.5
    9.       9.29 1H  singlet          CHx            -
N
N
Cl
N
N O
CH3
Cl
a
b'
b c
c'
d
e
f
h'
h
g
g'
i
i'
j
j'
k
l
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EXPANDED AROMATIC REGION
IR SPECTRAL STUDY OF 1,N-ARYL-2-PHENYL-4-(1',N-PHENYL-3'-(2”,4”-
DICHLOROPHENYL-4'-PYRAZOLYLMETHINO)-IMIDAZOLIN-5-ONES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R     C=O str.
      11a C6H5- 1718
11b 4-Cl-C6H4- 1712
11c 4-Br-C6H4- 1715
11d 4-F-C6H4- 1720
11e 4-NO2-C6H4- 1716
11f 3-NO2-C6H4- 1708
11g 3-Cl,4-F-C6H3 1714
11h 4-OCH3-C6H4- 1710
11i 3-OCH3-C6H4- 1706
11j 4-CH3-C6H4- 1718
11k 3-CH3-C6H4- 1713
11l 3,4-(Cl)2-C6H3- 1709
N
N
Cl
N
N O
CH3
Cl
a
b'
b c
c'
d
e
f
h'
h
g
g'
i
i'
j
j'
k
l
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N
N
Cl
N
N
O
CH3
Cl
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data it has been observed that all the compounds of
type (XI) were active against Gram positive and Gram negative bacterial species.
It was observed that the compounds showed good activity against Gram
positive bacteria. Maximum activity was observed in compounds having R=4-fluoro
phenyland 4-methoxyphenyl  against B.coccus. The compounds bearing R=4-fluorophenyl,
3-tolyl and 3-chloro,4-fluorophenyl have highly inhibited the growth of S.aureus.
Compounds with R=4-bromophenyl ,3-chloro,4-fluorophenyl and 4-methoxy
phenyl showed significant activity against Aerogenes. While the compounds bearing
R=4-nitrophenyl, 3-chloro,4-fluorophenyl and 4-methoxyphenyl have fairly inhibited
the growth Pseudomonas.
ANTIFUNGAL ACTIVITY
All the compounds were active against A.niger. Maximum activity was
observed by the compounds bearing R=4-chlorophenyl, 3-methoxy phenyl, and  3-tolyl.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared with
standard drug viz. greseofulvin.

INTRODUCTION
Azomethine derivatives have been found to be potent drug in pharmaceutical
industries and possess a wide spectrum of biological activity. Azomethines are also known
as schiff bases and they are well known intermediates for the preparation of azetidinones,
thiazolidinone, formazan, arylacetamide and many other entities of pharamaceutical
potential. These are the compounds containing characteristic –HC=N– group.
Azomethines are obtained mainly by warming  aldehyde & aromatic amine
together. Howeve, it is more convenient to work in a solvent such as alcohol,dilute acetic
acid or glacial acetic acid. Sometimes the reaction is aided by traces of acid in other
cases the hydrochloride of the amines can be used in the synthesis.In general Schiff
bases do not react further with either of the reagents used in their preparation as do
most of the other types of simple intermediates.
SYNTHETIC ASPECTS
Different methods for the preparation of azomethine derivatives documented in
literature are described as under.
1. A new one pot procedure for the generation of azomethine via chlorominium
salt has been investigated by Rosaleen J. Anderson and co-workers400.
2. General account of the summary of reaction of aldehydes with amine (aromatic
or aliphatic) has been reviewed by Murray401.
N
O
O
R2
CH3
O
R1 (COCl2) N
+ O
O
R2
CH3
Cl
R1
R H
O
+ R' NH2 N
R'
R
(II)
(I)
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3. Strache402 and Van Alphen403 have prepared imine in two steps.
a.  Addition of the amine to the carbonyl group of the aldehyde gives aldol.
 The aldol is rarely capable of isolation.
b.  The loss of water to give an imine (azomethine), this corresponds  to the
 “crotonaldehyde stage” of the aldol condensation.
4. Oddo & Tognacchini404  have introduced the comparative rates of formation
of Schiff base from aniline & substituted aniline & aromatic aldehyde .
THERAPEUTIC IMPORTANCE
Literature survey reveals that various azomethines have resulted in many potential
drugs and are known to possess broadn spectrum of biological activities.
1. Antiviral405
2. Antifungal406
3. Antiparasitic407
4. Antibacterial408
5. Antipyretic409
6. Antiinflammatory410
7. Plant hormone activity411
8. Antitubercular412
Smalders et al.413 synthesized some new azomethine as potential antitumor
agents. Sharaf El-Din, and Nabaweyal414 have synthesized some azomethine
derivatives (IV) having good antibacterial activity.Chohan et al.415 have synthesized
R H
O
+ R' NH2 NH R'R
OH
NH R'R
OH
N
R'
R + H2O
(III)
(III)
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azomethines, which have been  screened and compared for their antibacterial action
against bacterial  species Escherichia coli, Pesudomonus aeruginoase and Klebisella
pneumoniase.
Das Joydip & Singh, Anilk416 have synthesized azomethine derivatives  as shown
below.  All trans-N-refinylidene-n-butylanine (V) can be stabilized in liposomes of
phophatidylcholine. The rate of formation of the Schiff’s base is found to decrease with
increasing cholesterol concentration in the membrane.  Das Arima et al.417 have prepared
Schiff’s bases of  aminohydroxy guanidine (SB-AHG5) and tested  their antiviral  activity
against herpes simplex virus type I (HSV-1) and adenovirus type-5 (Ad-5)  along with
11 other heterocyclic SB-AHG5. Some of these compounds show good  antiadenoviral activity.
Ram Tilak et al.418 have synthesized some Schiff’s bases, thiazolidinones 4-
triazolines, and formazones of 2-chloro phenothiazines and screened against carrageenin-
induced edema in albino rats. The thiazolidinones showed promising antiinflammatory
activity. Pandey, Taruna et al.419 prepared azomethines and their boron complexes and
screened for their antifungal  and antibacterial properties. It is evident that azomethines
alone were quite toxic but their activity increased after complexation.
Sabrina Castellano et. al.420 have prepared azomethine derivatives and evaluated
in vitro against several pathogenic fungi responsible for human disease. B. Shivarama
Holla et. al.421 have documented antibacterial, antifungal and herbicidal activity of
azomethine derivatives.Wang, Yangsng and co-workers422 have screened some
R  =   3,4 -OH,
          3,4-NO2
N
OH
Me
R
(V)
N
But
Me Me MeMe
(IV)
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azomethines having good plant homone activity. Pascal Rotheist et. al.423 have reported
some new azomethines as antiparasitic agents.
 B. Shivarama Holla., et al.424 have synthesized azomethines of type (VI) having
antibacterial and anti-inflammatory activity. Dimmoch J. et. al.425  have reported azomethines
as cytotoxic agents.Adnan A. et. al.426 have studied azomethines possessing significant
antibacterial and antifungal activites.
Iana Vazzana et. al.427 have prepared derivatives (VII) and reported them
as antinflammatory agents. Neslishan and Reyhan428 have examined azomethines
and studied their antitumor activity. R. S. Varma429  has been demonstrated a series
of new azomethines and evaluated them for antileishmanial activity.
Recently, Parumal P. Selvam and co-workers430  have documented azomethine
derivatives as  antimicrobial agent.Zhanyong Guo et.al.431,432  have synthesised
schiff ’s base of carboxymethyl chitosan and reported their in vitro antifungal and
antioxident activity. Sham M. Sondhi et. al.433 have prepared azomethine
derivatives(VIII) and documented their anti-inflammatory, analgesic and kinase (CDK-1,
CDK-5, and GSK-3) inhibition activity.
Jayendra Patole et. al.434 have reported schiff’s base (IX) conjugates of p-
(VI)         R=2-NO2, 4-NO2, 4-Br,.....etc.
N
S
NH
N
O
Cl
Cl
Cl
R
N
N
R
R = 3-CF3, 4-SO2NH2,
       4-SO2CH3
(VII)
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amino salicyclic acid containing hydroxyl-rich side chains show enhanced
antimycobacterial activity against mycobacterium smegmatis and mycobaterium bovis
BCG. Alaaddin Cukurovali et. al.435 have designed and synthesized azomethine
derivatives and investigated their antibacterial and antifungal activity. Anti-HIV ativity of
schiff’s base have been reported by Dharmarajan and co-workers436.
Thus with an effort to capitalize the biological potential and to provide more
interesting compounds for biological study, we have undertaken the synthesis of
azomethines bearing pyrazole nucleous.
SECTION-I  :  SYNTHESIS AND THERAPEUTIC EVALUATION OF N-ARYL-
   1,N-PHENYL-3-(2’,4’-DICHLOROPHENYL)-PYRAZOL-4-YL-
   AZOMETHINES
SECTION-II  :  S Y N T H E S I S  A N D  T H E R A P E U T I C  E VA L U AT I O N  O F
     4-ARYLAMINOMETHYL-1,N-PHENYL-3-(2’,4’- DICHLORO-
    PHENYL)PYRAZOLES
N
OH
O
OH
OH
(IX)
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF N-ARYL-1,N-PHENYL-3-
(2’,4’-DICHLOROPHENYL)-PYRAZOL-4-YL-AZOMETHINES
Azomethine derivatives are well known for their pharmacological activities.
Azomethines are also found as intermediate in organic synthesis. These findings
encouraged us to synthesise some new azomethines of type (XII) bearing pyrazole
nucleus. The synthesis was carried out by the condensation of 1,N-phenyl-3-(2’,4’-
dichlorophenyl)-4-formyl pyrazole wth different aromatic amines.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
R-NH2
gl. CH3COOH
N
N
CHO
Cl Cl
N
N
N
R
Cl Cl
Type (XII)   R = Aryl
EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF N-ARYL-1,N-PHENYL-3-
(2’,4’-DICHLOROPHENYL)-PYRAZOL-4-YL-AZOMETHINES
(A) Synthesis of 2,4-Dichlorophenylhydrazone143
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole144
See [A] Part-I, Section-I (B).
(C)  Preparation of N-(p-Anisyl)-1,N-phenyl-3-(2’,4’-dichlorophenyl)-pyrazol-4-yl-
 azomethines
A mixture of 1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole(3.17gm,
0.01M) and p-anisidine (1.23gm, 0.01M) was refluxed in ethanol (95%) for 10 hrs.
using gl. CH3COOH as catalyst. The contents were cooled and product isolated was
crystallised from ethanol. Yield, 86%, m.p.170oC, (C23H17Cl2N3O; Found : C, 65.41;
H, 4.06; N, 9.95 %; Required : C, 65.43%; H, 4.09%; N, 10.12%).
TLC solvent system : Acetone : Benzene (2.3:7.7).
Similarly other substituted azomethines have been prepared. The physical data
are recorded in Table No. 12.
(D) Antimicrobial activity of N-Aryl-1,N-phenyl-3-(2’,4’-dichlorophenyl)-
pyrazol- 4-yl-azomethines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 12.
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IR  SPECTRAL STUDY OF N-(p-ANISYL)-1,N-PHENYL-3-(2’,4’-DICHLOROPHENYL)-
PYRAZOL-4-YL-AZOMETHINE
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/b h3
 534.2
 553.5
 630.7
 686.6
 756.0
 821.6
 858.3
 902.6
 972.1
1016.4
1078.1
1101.3
1205.4
1232.4
1299.9
1363.6
1434.9
1502.4
1533.3
1583.4
1645.2
2817.8
2923.9
3049.2
3400.3
N
N
N
Cl
Cl
O
CH3
 Observed
Alkane C-H str. (asym.) 2923 2975-2950 515
-CH3 C-H str. (sym.) 2817 2880-2860   “
C-H i.p.def. (asym.) 1434 1470-1400   “
C-H o.o.p. def. (sym.) 1363 1390-1370   “
Aromatic C-H  str. 3049 3080-3030 516
C=C str. 1533 1585-1480   “
C-H i.p. def. 1101 1125-1090   “
C-H o.o.p. def  821    835-810   “
Pyrazole C=N str. 1583 1630-1590 517
moiety C-N str. 1078 1230-1020  “
C-Cl str.  756                 830-560  “
Ether C-O-C str. (asym.) 1232 1275-1200 515
C-O-C str. (sym.) 1066 1075-1020   “
Schiff Base C=N str.                              1645 1660-1580 517
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR  SPECTRAL STUDY OF N-(p-TOLYL)-1,N-PHENYL-3-(2’,4’-DICHLOROPHENYL)-
PYRAZOL-4-YL-AZOMETHINES
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference  J Value
  In Hz
1. 2.34 3H singlet          Ar-CH3          -
2. 7.04 2H doublet         Ar-Hgg’              Jgh = 8.1
3. 7.14 2H doublet         Ar-Hbb’    Jbb’= 8.1
4. 7.33 2H multiplet       Ar-Hae                     -
5. 7.47 4H multiplet       Ar-Hcc’+Ar-Hd
                   +Ar-Hf                     -
   6. 7.79 2H doublet         Ar-Hhh’    Jhg = 8.5
7. 8.26 1H singlet          CHx           -
8. 8.66 1H singlet          Ar-Hi           -
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EXPANDED AROMATIC REGION
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that the compounds bearing
R=phenyl and 4-fluorophenyl  have displayed good activity against B.coccus. The
compounds bearing R=4-anisyl, 2-nitrophenyl and 3,4-dichlorophenyl have shown
considerable activity against S.aureus.
In case of Gram negative bacterial strains all the compounds were inactive against
E. aerogenes except the compound bearing R=4-tolyl and 3,4-dichlorophenyl.  While
the compounds bearing R=phenyl, 3-nitrophenyl, and  3-chloro,4-fluorophenyl showed
significant activity against P. aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested
species. However, the compounds having R=4-bromophenyl and 2,4-dichlorophenyl
displayed highest activity against A.niger.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicillin, ciprofloxacin, erythromycin and antifungal activity was compared with
standard drug viz. greseofulvin.
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SECTION - II
SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYLAMINOMETHYL-
1,N-PHENYL-3-(2’,4’-DICHLOROPHENYL)-PYRAZOLES
The efficiency of arylaminomethyl derivatives as chemotherapeutic agents
is well established. To further assess the pharmacological profile of such a class of
compounds, we have synthesised arylaminomethyl derivatives of type (XIII) by
selective reduction of (Imine group) shiff’sbase of (XII) with sodiumborohydride
in controlled experimental condition as shown in the reaction schime.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with standard
drugs.
N
N
NH
R
Cl Cl
N
N
N
R
Cl Cl
An. NaBH4
   Type (XIII)       R = Aryl
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYLAMINOMETHYL-
1,N-PHENYL-3-(2’,4’-DICHLOROPHENYL)-PYRAZOLES
(A) Synthesis of 2,4-Dichlorophenylhydrazone143
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole144
See [A] Part-I, Section-I (B).
(C) Synthesis of N-Aryl-1,N-phenyl-3-(2’,4’-dichlorophenyl)-pyrazol-4-yl-azomethines
See Part-VII, Section-I (C).
(D) P r e p a r a t i o n  o f  4 - (p - A n i s y l ) a m i n o m e t h y l - 1 , N - p h e n y l - 3 - ( 2 ’ , 4 ’ -
dichlorophenyl)pyrazole
Sodium borohydride (0.15M, 0.57g) was added to a methanolic solution
of N-(p-anisyl)-1,N-phenyl-3-(2’,4’-dichlorophenyl)-pyrazol-4-yl-azomethine (0.01M,
4.22gm) over a period of 30 minutes at temperature 5-10oC. The reaction mixture then
kept over night at room tempeture. The excess borohydride was neutralized by adding
water and the product was extracted with ether.The ether extract was washed with water
untill extract is neutralised, then dried over anhydrous Na2SO4 and finally the ether was
evaporated to give aminomethyl derivative. Yield, 55%, m.p. 124oC.(C23H19Cl2N3O;
Found : C, 65.10; H, 4.51; N, 9.90 %; Required : C, 65.15%; H, 4.53%; N, 9.78%).
TLC solvent system : Acetone : Benzene (1.5 : 8.5).
Similarly other substituted arylaminomethyl derivatives have been prepared. The
physical data are recorded in Table No. 13.
(E) Antimicrobial activity of 4-Arylaminomethyl-1,N-phenyl-3-(2’,4’-
dichlorophenyl)pyrazole
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 13.
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IR SPECTRAL STUDY OF 4-(p-ANISYL)AMINOMETHYL-1,N-PHENYL-3-
(2’,4’-DICHLOROPHENYL)-PYRAZOLES
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
750.01000.01250.01500.01750.02000.03250.0
 650.0
 690.5
 756.0
 840.9
 921.9
 956.6
1004.8
1053.1
1114.8
1157.2
1174.6
1245.9
1288.4
1342.4
1406.0
1446.5
1502.4
1544.9
1598.9
2854.5
2923.9
2977.9
3045.4
3404.1
 Observed
Alkane C-H str. (asym.) 2923 2975-2950 515
-CH3 C-H str. (sym.) 2854 2880-2860   “
C-H i.p.def. (asym.) 1446 1470-1400   “
C-H o.o.p. def. (sym.) 1342 1390-1370   “
Aromatic C-H  str. 3045 3080-3030 516
C=C str. 1544 1585-1480   “
C-H i.p. def. 1114 1125-1090   “
C-H o.o.p. def  840    835-810   “
Pyrazole C=N str. 1598 1630-1590 517
moiety C-N str. 1053 1230-1020   “
C-Cl str.  756                 830-560 515
Ether C-O-C str. (asym.) 1245 1275-1200   “
C-O-C str. (sym.) 1053 1075-1020   “
                                    (overlapped)
C-N str. 1157 1250-1000   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
N
N
NH
Cl
Cl
O
CH3
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PMR SPECTRAL STUDY OF 4-(p-ANISYL)AMINOMETHYL-1,N-PHENYL-3-
(2’,4’-DICHLOROPHENYL)-PYRAZOLES
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
a
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Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1.   3.35 3H singlet Ar-OCH3           -
2.   4.17 2H singlet CH2           -
3.   7.08 2H doublet Ar-Hgg’               Jgh = 8.1
4.   7.15 2H doublet Ar-Hbb’     Jbc = 8.1
5.   7.36 2H multiplet Ar-Hae                       -
6.   7.52 4H multiplet Ar-Hd+Ar-Hcc’
Ar-Hf -
   7.   7.82 2H doublet Ar-Hhh’     Jhg = 8.8
8.   8.26 1H singlet CHx           -
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EXPANDED AROMATIC REGION
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    Sr.     R   Molecular    Molecular       M. P.         Rf*     Yield      % of Nitrogen
    No.    Formula      Weight         oC       Value       %             Calcd.        Found
1     2        3          4          5          6                  7                 8        9
   13a C6H5- C22H17Cl2N3    394  118 0.48 60    10.66      10.73
13b 4-OCH3-C6H4- C23H19Cl2N3O 424 124 0.42 55  9.90  9.78
13c 4-CH3-C6H4-- C23H19Cl2N3 408 115 0.73 58 10.29 10.42
13d 4-F-C6H4- C22H16Cl2FN3    412  132 0.55 56    10.19      10.31
13e 4-Cl-C6H4- C22H16Cl3N3 428 125 0.58 58  9.80  9.68
13f 4-Br-C6H4- C22H16BrCl2N3    473  140 0.63 62     8.88       9.01
13g 2-NO2-C6H4- C22H16Cl2N4O2    439  112 0.68 59    12.75      12.68
13h 3-NO2-C6H4- C22H16Cl2N4O2    439  126 0.60 61    12.75      12.68
13i 3-Cl,4-F-C6H3- C22H15Cl3FN3    446  133 0.59 63     9.41       9.65
13j 2,4-(Cl)2-C6H3- C22H15Cl4N3    463  122 0.62 57     9.07       9.20
13k 3,4-(Cl)2-C6H3- C22H15Cl4N3    463  110 0.65 56     9.07       9.20
13l 2-OCH3-C6H4- C23H19Cl2N3O    424  125 0.78 61     9.90      10.18
TABLE-13 : PHYSICAL CONSTANTS OF  4-ARYLAMINOMETHYL-1,N-PHENYL-3-(2’,4’-DICHLOROPHENYL)-
PYRAZOLES
*TLC Solvent System :Ethylacetate : Hexane (1.5 : 8.5)
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GRAPHICAL CHART NO. 13 :  ANTIMICROBIAL ACTIVITY OF 4-ARYLAMINOMETHYL-1,N-PHENYL-3-(2’,4’-
DICHLOROPHENYL)-PYRAZOLES
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E. aerogenes 15 20 14 19 18 15 17 13 15 10 16 20 20 21 22 19 0
P. aeruginosa 18 14 19 15 21 12 14 18 16 20 14 18 22 21 16 23 0
A. niger 16 12 14 16 20 15 21 19 14 16 10 14 0 0 0 0 26
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that the compounds bearing
R=4-anisyl and 2-nitrophenyl  have displayed good activity against B.coccus. The compounds
bearing R= 2,4-dichlorophenyl have shown considerable activity against S.aureus.
In case of Gram negative bacterial strains all the compounds were inactive against
E. aerogenes except the compound bearing R=4-anisyl and 3-chloro,4-fluorophenyl.
While the compounds bearing R=4-chlorophenyl and 2,4-dichlorophenyl showed significant
activity against P. aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested
species. However, the compounds having R=4-chlorophenyl and 2-nitrophenyl
displayed highest activity against A.niger.
The antibacterial activity was compared with standard drugs viz.amoxicillin,
benzoylpenicil l in,  ciprofloxacin,  erythromycin and antifungal activity was
compared with standard drug viz. greseofulvin.
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INTRODUCTION
Nitriles are reported to possess various therapeutic activities, but due to their
high toxicity, they have low therapeutic importance. The term ‘Nitrile’ was first introduced
by Febung437 in 1844. The first synthesis of nitrile has been reported by Wohler and
Liebig438 in 1832 and Poleuze439 in 1834. They are very much useful as intermediates
for various products such as acrylonitrile for plastic, synthetic rubber and fibers,
phthalonitrile for dye stuff.The simplest form of the organic nitrile is acetonitrile, often
used as solvent.
SYNTHETIC ASPECTS
Few recent methods for the preparation of nitriles are as mentioned below.
1. Stephen A. Dibiase et. al.440 have synthesised E-& Z-cinnamonitriles from
aryl aldehyde or ketones in presence of acetonitrile and potassium hydroxide.
2. Takahiro Nishimura et.al.441 have synthesised nitriles by the ring cleavage reaction
of cyclobutanone-o-benzoyloximes.
3 . Barahman Movassagh and Salman Shokri442 have prepared nitriles from aryl/
alkyl aldehydes on treatment with NH2OH.HCl and KF/Al2O3 in one pot.
Ar
N
CH3CN
KOH
Ar CHO
(I)
R1,R2,R3 = Alkyl
NH2OH.HCl, KF/Al2O3
DMF/ 100 C
R CHO R CN
R = Alkyl or aryl(III)
R1
R2
N
R3
OBz
[Ir(cod)Cl]2
9, 10 - dihydroanthracene
K2Co3, DMF 50 c
N
R3
R1
R2
(II)
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4. Florencio Zaragoza443 has suggested method for preparation of nitriles from
alcohols.
5. Masanori Hatsuda and Masahiko Seki444 have synthesised nitriles
through cyanation of aryl/heteroaryl bromides employing heterogeneous Pd/C.
MECHANISM
The mechanism of nitrle formation is shown as under.
Reaction between CN and aldehyde is a type of nucleophilic substitution reaction.
From the above reaction, it can be seen that a nucleophile (CN) attacks on the carbonyl
carbon of aldehyde and yields cyanohydrin which reacts with amine to yield nitrile
derivatives.
THERAPEUTIC IMPORTANCE
They shows various therapeutic activities which are described as under.
1.  Antiinflammatory445
R OH Me3P
CN
+
I
_+ (i) DIPEA, EtCN
(ii) H2O
R
CN
(IV)
+ Zn(CN)2
Pd/C, Zn, ZnBr2, PPh3
DMA
Ar Br Ar CN
(V)
O
H
R
+ CN
O
CN
R
H
OH
CN
H
R
R1-NH2
-H2O
NH
CN
H
R
R1
H+
. .
_
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2.  Antihypoxic446
3.  Central nervous system agent447
4.  Pesticidal448
5.  Antihypertensive449
6.  Fungicidal450
7.  Antiarrythemic451
8.  Antimicrobial452
9.  Herbicidal and Viricidal453
Peterson I. A. and co-workers454 have syynthesised some nitrile derivatives
and reported their antiapoptotic activity.Nitrile with fused pyridine ring were reported
as ulcer inhibitor by Shepherd R. G.455.Nobuyuki et.al.456 have investigated some nitriles
of type (VI) as tumor necrosis factor production inhibitor.
Virinder S. Parmer et.al.457 have synthesised series of nitrile derivatives of type
(VII) and reported as antioxidant agents. Parlo Sanna et.al458. have synthesised nitriles
(VIII) and screened for their antitubercular activity. Shibata Yasushi and co-workers459
have reported nitrile as insectides. Yogihara and co-wirkers460 have documented
antimicrobial and antiinflammatory activity of nitriles.
S
O
O N
N
N N
H
CH3
O
(VI)
N
N
N
N
NH2
N N
Br
F
CN
N
H
(VIII)(VII)
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Iwanowicz E. J. et. al.461 have synthesised nitriles (IX) and found preventing
and treating IMPDH associated disorders, such as transplant rejection and autoimmune
disease.Norsyrava et.al.462 have formulated novel nitriles possessing  muscle relaxant
activity.Bernard M. et. al.463 have investigated nitriles as thromboxane receptor
antagonists.
Suzana Jovanovic et. al.464 have suggested antiestrogenic activity of some
nitrile derivatives.M. Hiroshi et. al.465 have investigated some new nitriles and
studied their pesticidal and marinantifouling activity. Cyanoguanidine derivative (X)
has been synthesised and reported as inhibitors of mitochondrial F, FO, ATPase by
A. Karnails et al.466.
Nurolaini Kifli et. al.467 have discovered nitriles and reported their antiviral
activity.Miroslav Otmar et. al.468 have formulated nitriles possessing antiproliferative
activity.Marion Nipper et. al.469 have prepared nitriles useful as antimicrobial agent.
Ian J. S. Fairlamb et. al.470 have prepared nitrile derivatives and tested for their
antimicrobial activity.
Guohua Zhao et.al.471 have synthesised nitrile derivatives of type(XI) and
reported as potent dipeptidyl peptidase IV inhibitors.S. Srinivasan et.  al.472
have investigated nitriles which showed antimicrobial activity. Olivier Nicolas
and co-workers473 have discovered nitrile derivatives possessing moderate
antimalarial activity.
N N
N
NH2
S
CH3
N
(IX)
CF3
F3C
N
N
NH N
CN
NH
Cl Cl
(X)
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CONTRIBUTION FROM OUR LABORATORY
F. M. Bharmal and H. H. Parekh474  have synthesised newer acetonitriles (XII)
bearing quinoline moiety and tested them as antimicrobial agent.
Recently, Henrik Fuglsang and co-workers475 have reported dipeptidyl nitriles
as human dipeptidyl peptidase I inhibitors.Eva Altmann et.al.476 have sunthesised nitrile
derivatives(VIII) as inhibitors of  Cathepsin K. Jon Bondebjerg and co-workers477
have identified a potent and selective inhibitor of human dipeptidyl peptidase I by using
a dipeptide nitrile scaffold.
The synthesis of nitriles is of current interest owing to their enormous occurance
in biologically active derivatives. Hence, considerable attention has been focused on the
study of pharmaceutical important nitriles bearing pyrazole nucleus as described below.
SECTION - I  :  SYNTHESIS  AND BIOLOGICAL EVALUATION OF α -
     ARYLAMINO-[1’,N-PHENYL-3’-(2”,4”-DICHLOROPHENYL)-
     PYRAZOL-4’-YL]-ACETONITRILES
(XI)
NH
N
H
O
N
CN
N
Cl
N
CH3
Cl
NH
R
N
(XII) (VIII)
O
R NH
O
NH N
CH3 CH3
O
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF α-ARYLAMINO-[1’,N-
PHENYL-3’-(2”,4”-DICHLORO)PHENYL-PYRAZOL-4’-YL]-ACETONITRILES
The efficiency of nitrile derivatives as chemotherapeutic agents is well established.
To further assess the pharmacological profile of such a class of compounds, we have
synthesised nitrile derivatives of type  (XIV)  by the reaction of 1,N-Phenyl-3-(2’,4’-
dichlorophenyl)-4-formyl pyrazole with different aromatic amines in the presence of
potassium cyanide and glacial acetic acid at 0-50C.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all the compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with standard
drugs.
N
N
Cl
NH
R
N
Cl
N
N
Cl
CHO
Cl
R-NH2, KCN, 0-5  C
gl. CH3COOH
Type (XIV)     R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF α-ARYLAMINO-[1’,N-
PHENYL-3’-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4’-YL]-ACETONITRILES
(A) Synthesis of 2,4-dichlorophenylhydrazone143
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole144
See [A] Part-I, Section-I (B).
(C) Synthesis of α-p-Anisylamino-[1’,N-phenyl-3’-(2”,4”-dichlorophenyl)-
pyrazol- 4’-yl]acetonitrile
1,N-Phenyl-3-(2’,4’-dichlorophenyl)-4-formyl pyrazole (3.17 g, 0.01M)
dissolved in ethanol (25ml) was added to potassium cyanide (0.64g, 0.01M) dissolved
in water (15 ml) followed by glacial acetic acid (12 ml). The contents were then stirred
for 5 minutes to form cyanohydrin at 0oC. p-Anisidine (1.23g, 0.01M) dissolved in
methanol was added to the reaction mixture, contents were stirred at room temperature
for 24 hrs. The content was poured onto curshed ice. The solid product was filtered and
crystallised from ethanol. Yield 62%, m.p. 150oC (C24H18Cl2N4O; Required : C,
64.15; H, 4.04; N, 12.47;  Found : C, 64.17.; H, 4.08; N, 12.59%).
TLC solvent system : Ethylacetate : Hexane (1.8 : 8.2).
Similarly other substituted nitriles have been prepared. The physical data
are recorded in Table No. 14.
(E) Ant imicrobia l  ac t iv i ty  o f  α -ary lamino- (1 ’ ,N-phenyl -3 ’ - (2” ,4”-
d ich lorophenyl ) -  pyrazo l -4 ’ -y l ) -ace toni tr i l e s
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 14.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF α-P -ANISYLAMINO-[1’ ,N-PHENYL-3’-(2”,4”-
DICHLOROPHENYL)-PYRAZOL-4’-YL]ACETONITRILE
 Observed
Alkane C-H str. (asym.) 2920 2975-2950 515
-CH3 C-H str. (sym.) 2866 2880-2860   “
C-H i.p.def. (asym.) 1454 1470-1435   “
Aromatic C-H str. 3033 3080-3030   “
C=C str. 1502 1585-1480 516
C-H i.p. def. 1062 1125-1090   “
C-H o.o.p. def  815    835-810   “
Pyrazole C=N str. 1600 1630-1590 517
moiety C-N str. 1159 1230-1020   “
C-Cl str.  759                 830-560 515
Ether C-O-C str. (asym.) 1217 1275-1200   “
C-O-C str. (sym.) 1062 1075-1020   “
                                                          (overlapped)
Nitrile C≡N str. 2237 2240-2220 518
N-H str. 3332 3350-3200   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 439.7
 522.7
 605.6
 692.4
 740.6
 759.9
 815.8
 844.8
 920.0
 958.6
1012.6
1062.7
1126.4
1155.3
1217.0
1271.0
1357.8
1413.7
1454.2
1502.4
1515.9
1554.5
1600.8
2237.3
2866.0
2920.0
3033.8
3332.8
N
N
Cl
NH
N
OCH3
Cl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF α-P-ANISYLAMINOAMINO-(1’,N-PHENYL-3’-O-
ETHOXYPHENYL-PYRAZOL-4’-YL)ACETONITRILE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1.      2.25 3H  singlet Ar-CH3          -
2.      5.36 1H  singlet CHi                    -
3.      6.56 2H  doublet Ar-Hgg’              Jgh = 8.2
4.      7.03 2H  doublet Ar-Hbb’    Jbc = 8.0
5.      7.28 2H  doublet Ar-Hae          -
6.      7.37 1H  triplet Ar-Hd    Jde = 1.9
7.      7.48 3H  multiplet Ar-Hcc’,Ar-Hf          -
8.      7.72 2H  doublet Ar-Hhh’    Jhg = 7.8
9.      8.29 1H  singlet CHx          -
N
N
Cl
NH
N
Cl
O
CH3
a
b
f
x
h
h'
g'
g
i
b'
c
c'
d
e
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EXPANDED AROMATIC REGION
IR SPECTRAL STUDY OF α-ARYLAMINO-[1’,N-PHENYL-3’-(2”,4”-DICHLORO
PHENYL)-PYRAZOL-4’-YL]ACETONITRILES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R
      14a C6H5- 2218
14b 4-OCH3-C6H4- 2237
14c 4-CH3-C6H4- 2225
14d 4-F-C6H4- 2228
14e 4-Cl-C6H4- 2212
14f 4-Br-C6H4- 2230
14g 2-NO2-C6H4- 2217
14h 3-NO2-C6H4- 2232
14i 3-Cl,4-F-C6H3- 2236
14j 2,4-(Cl)2-C6H3- 2216
14k 3,4-(Cl)2-C6H3- 2225
14l 4-OCH3-C6H4- 2219
C≡N str.
N
N
Cl
NH
N
Cl
O
CH3
a
b
e'
x
h'
g'
g
i
b'
c c'
d
e
h
NN
Cl
NH
N
Cl
Cl
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ZONE OF INHIBITION IN mm B.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that the compounds bearing
R=4-tolyl , 2-nitrophenyl and 3,4-dichlorophenyl have displayed good activity against
B.coccus. The compounds bearing R=4-bromophenyl and 3-chloro-4-fluorophenyl  have
shown considerable activity against S.aureus.
In case of Gram negative bacterial strains all the compounds were inactive against
Aerogenes except the compound bearing R=phenyl and 4-bromophenyl. While the
compounds bearing R=2-nitrophenyl, and  2,4-dichlorophenyl showed significant activity
against Pseudomonas.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested
species. However, the compounds having R=4-tolyl, 3-chloro-4-fluorophenyl, and 2-
methoxyphenyl displayed highest activity against A.niger.
The antibacterial activity was compared with standard drug viz.amoxicillin,
benzoylpenicil l in,  ciprofloxacin,  erythromycin and antifungal activity was
compared with standard drug viz. greseofulvin.

MICROWAVE INDUCED SYNTHESIS
INTRODUCTION
In the last few years Microwave induced Organic Reaction Enhancement (MORE)
chemistry has gained popularity as a non-conventional technique for rapid organic
synthesis478 & many researchers have described accelerated organic reaction and a
large number of papers has appeared proving the synthetic utility of MORE chemistry in
routing organic synthesis. It can be termed as "e-chemistry" because it is easy, effective,
economical and eco-friendly and is believed to be a step to-wards green chemistry.
High speed microwave synthesis has attracted a considerable amount of attention
in recent years. Since the first reports on the use of microwave heating to accelerate
organic chemical transformations by the groups of Gedye and Giguere/Majetich in 1986,
microwave assisted organic chemistry has experienced exponential growth since mid-1990.
Microwave heating is very efficient energy source and can be used to significantly
reduce reaction time of numerous organic reactions. It allows preparation of numbers of
compounds at the same time in microwave cavity. Therefore it is very useful in parallel
synthesis and combinatorial synthesis. Moreover, can lead to improve isolated yields
compared to conventional technology.  Microwave assisted organic synthesis [MAOS]
provides an efficient alternative for the synthetic chemist.
Microwave heating is distinguished primarily by being a radiant process. Its
relationship to ordinary heat is of much interest. Regular heat rays differ in frequency
and properties. In the conventional method, heat is generated by molecular collisions
which accomplish the energy transfer while microwaves cause heating through the
absorption of energy quanta. Microwave generate instantaneous “ incore” heating of
materials, in a homogeneous and selective manner, especially those with poor heat
conduction properties.
The microwave region of the electromagnetic spectum lies between 1 cm and 1 m
and in order to aviod interfering with radar and telecommunication activities which operate
within this region, most domestic and commercial microwave instruments operate at
2.45 GHz. The heating effect utilised in microwave assisted organic transformations is
due in the main, to dielectric polarisation, although conduction losses can be important
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particularly at higher temperatures. Whilst the polarisability of a molecule (determined
by the Debye equation) is the sum of a number of contributions, only dipolar and interfacial
polarisation are important to heating effects associated with microwave irradiation.
Mechanism
The mechanisms associated with microwave heating are dipole rotation and ionic
conduction. When a molecule is irradiated with microwaves it will attempt to align itself
with the electric field by rotation. If the frequency of molecular rotation is similar to the
frequency of microwave radiation (2.45GHz), the molecule will continuously align and
realign itself with the oscillating field, therefore the electric energy is absorbed by the
molecule. It is obvious that compounds with large dielectric constants tend to absorb
energy readilyunder microwave irradiation. The interfacial polarisation, the
Maxwell-Wagner effect, may also contribute to the heating effect when the conducting
particles are in contact with a non conducting medium, e.g. in heterogenous reactions. It
is particularly convenient that qualitatively the larger the dielecric constant, the greater
the coupling with microwaves. Thus solvents such as water, methanol, DMF, ethyl acetate,
chloroform, acetone, acetic acid, dichloromethane and R-spirit are all heated when
irradiated with microwaves. Non-polar solvents like CCl4, toluene, xylene, diethylether
do not couple and therefore do not heat with microwave irradiation.
APPLICATIONS IN ORGANIC SYNTHESIS
The first applications of microwave ovens in organic synthesis began very
recently. In the first experiments, Gedye479 and then Giguere480, provided evidence for
dramatic accelerations in some classical organic reactions and these were ascribed to
temperature and pressure effects, when performed in closed teflon vessels. Since solvents
were used in these experiments, some problems with safe operation appeared, and
explosions sometimes resulted. Further developments demonstrated the potential of solvent
free reactions to solve these problems and to facilitate the scale up of preparative runs.
Recently, reactions under dry conditions using inorganic reagents are gaining more
attention because of their enhanced selectivity and milder conditions than those associated
with conventional homogeneous reaction procedures. It should be noted that some of
219Microwave synthesis...
the inorganic additives reach temperatures in excess of 1000oC very rapidly and
decomposition of materials may be problematic, therefore some precautions regarding
superheating and associated fire hazards or explosions are taken.
Three types of solvent free procedures can be coupled with microwave activation.
(i) reactions between heat reactants, needing at least one polar molecule, as liquid-liqu or
liquid solid systems. In this later case, reactions presumably occur at the interface
due to absoprtion of the liquid reactant at the surface of the solid one.
(ii) Reactions between supported reagents on solid mineral supports in dry media by
impregnation of compounds on alumina, silicas or clays.
(iii) Phase Transfer Catalysis (PTC) conditions in the absence of organic solvent, i.e.
when a liquid reagent acts both as a reactant and an organic phase. This last
methodology can also be improved under sonochemical activation.
Microwave heating has emerged as a powerful technique to promote a variety of
chemical reactions.481 Microwave reaction under solvent-free conditions are attractive
in offering reduced pollution and offer low cost together with simplicity in processing
and handling482. The recent introduction of microwave synthesis has gained acceptance
and popularity among the synthetic chemist community & it includes virtually all types of
chemical reactions such as Diels-Alder483, Claisen484, Vilsmeier485, Oxidation486,
Substitution487,488,Cyclisation489,490,Catalytictransfer hydrogenation491,492,Knoevenagel
condensation493, oxime synthesis494, alkylation495, decarboxylation496, etc.
Malhotra V. et. al.497 have demonstrated one-pot condensation of chalcones
with thiosemicarbazide in ethanol under strogly basic condensation. Microwave enhanced
esterification of α,β-unsaturated acids have been carried out by Kumar Mitra & co-
workers498. Microwave assisted fungicidal 1,2,4-traizines, 1,2,4-tetrazoles, pyrazoles
and triazoles have been synthesised by Mazahir Kidwai & co-workers499.Microwave
assisted Pall-Knorr condensation was carried out by G. Minetto& co-worker500.
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Some other organic synthesis like 1,2-dihydropyridines501, phthalimide502, &
quinazolinone503 derivatives etc. also enhanced by the microwave irradiation.
Recently, microwave assisted some new organic reactions have been carried out
which include synthesis of pyrazolines504,505, isoxazoles506, cyanopyridines507,
quinoxalines and heterocyclic pyrazines508, N-aryl phtalamic acids509, substituted 2-
pyr idones510 ,su l fonylbenz imidazo le -4 ,7 -d iones511,aminopyr id ines512
imiodylbenzotraizoles513, arylamines514 with better biological activities.
Microwave assisted chemical reactions are gaining importance due to advantages
and environmentally friendly process they offer as compared to conventional reactions.As
a part of ongoing research towards the non-traditional approach to the experimental
setup of organic reaction, the concept of microwave enhanced reaction has been utilised
for rapid and efficient synthesis of  1,N-acetyl-3-aryl-5-[1',N-phenyl-3'-(2”,4”-
dichlorophentl)-pyrazol-4'-yl]-pyrazolines and 2-methoxy-3-cyano-4-{1’,N-phenyl-3’-
(2”,4”-dichlorophenyl)-pyrazole-4’-yl]-6-aryl pyridines. Q. Pro-M microwave oven is
used as a microwave irradiation source and compared in terms of yield and reaction
period and have been cited in Talbe No. 3a and 7a
SECTION-I :  MICROWAVE ENHANCED SYNTHESIS OF 1,N-ACETYL-
3 - A R Y L - 5 - [ 1 ' , N - P H E N Y L - 3 ' - ( 2 ” , 4 ” -
DICHLOROPHENYLPYRAZOL)-4'-YL]-PYRAZOLINES
SECTION-II:  MICROWAVE ENHANCED SYNTHESIS OF 2-METHOXY-3-
C Y A N O - 4 - [ 1 ’ , N - P H E N Y L - 3 ’ - ( 2 ” , 4 ” -
DICHLOROPHENYL)PYRAZOL-4’ -YL]-6-ARYL-
PYRIDINES
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SECTION - I
MICROWAVE ENHANCED SYNTHESIS OF 1,N-ACETYL-3-ARYL-5-[1',N-
PHENYL-3'-(2”,4”-DICHLOROPHENYL)-PYRAZOL-4'-YL]-PYRAZOLINES
As microwave used to creat effect in organic synthesis, the “in situ” generation of
heat is very efficient and can be used to signifi cantly reduce reaction times of synthetically
useful organic transformations. Thus microwave assisted organic synthesis has advantages
over conventional techonology. We have synthesised pyrazoline derivatives of type (III)
by the reaction of chalcone with hydrazine hydrate in glacial acetic acid under microwave
irradiation as cited under.
The constitution of the synthesized products have been characterized by
using elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry. Purity of all compounds have been
checked by thin layer chromatography.
The compounds of  type (III) have been already synthesised using
conventonal method as reported earlier in Part-I, section-III (D), page No. 45
Q. Pro-M Microwave Oven, Questron Technologies corporation-CANADA,
sample preparation system : 220 VAC, 60 Hz is used as a microwave irradiation
source and data are compared in terms of yield and reaction period have been cited
in Table No. 3a.
gl. CH3COOHNH2NH2H2O ,
N
N
R
O
Cl Cl
N
N
Cl Cl
N
N R
O
CH3
microwave irradiation 
10 - 12mins.
DMF
Type (III)    R = Aryl
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TABLE NO. 3a   :  COMPARISON OF CONVENTIONAL METHOD AND
MICROWAVE INDUCED SYNTHESIS OF 1,N-ACETYL-
3-ARYL-5-[1',N-PHENYL-3'-(2”,4”DICHLOROPHENYL)-
PYRAZOL-4'-YL]-PYRAZOLINES
Comp.
  No.
R Thermal Microwave M. P.
 oCReaction
Period (hrs.)
Yield
  %
Reaction
Period (min.)
  3a C6H5- 10 65  12 67 150
3b 4-OCH3-C6H4- 12 68  12 71 148
3c 4-CH3-C6H4- 11 70  10 72 162
3d 4-Cl-C6H4- 10 62  10 65 120
3e 4-F-C6H4- 10 65  11 68 125
3f 4-Br-C6H4- 10 72  12 75 148
3g 4-OH-C6H4- 12 70  12 73 128
3h 2-OH-C6H4- 11 73  10 76 115
3i 4-NO2-C6H4- 11 67  12 70 138
3j 3-NO2-C6H4- 13 68  11 71 135
3k 2,4-(Cl)2-C6H3- 10 62  12 65 118
3l 4-NH2-C6H4- 11 70  10 73 152
Yield
  %
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SECTION - II
MICROWAVE ENHANCED SYNTHESIS OF 2-METHOXY-3-CYANO-4-[1',N-
PHENYL-3'- (2”,4”-DICHLOROPHENYL)PYRAZOL-4'-YL]-6-ARYL
PYRIDINES
As a part of our research programme towards the non traditional approach to the
experimental set up of organic reactions, the concept of “Microwave induced Organic
Reaction Enhancement” (MORE) chemistry has been utilised for rapid and efficient
synthesis of cyanopyridine derivatives of type (VII).The synthesis was carried out by
the condensation of chalcones of type (I) with malononitrile in the presence of sodium
methoxide under microwave irradiation as cited under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by
thin layer chromatography.
The compounds of  type (VII) have been already synthesised using conventional
method as reported earlier in Part-III, section-I (D), page No. 111
Q. Pro-M Microwave Oven, Questron Technologies corporation-CANADA, sample
preparation system : 220 VAC, 60 Hz is used as a microwave irradiation source and
data are compared in terms of yield and reaction period have been cited in Table No. 3a.
R = ArylType - (VII)
N
N
O
R
Cl
Cl
CH2.(CN)2 ,
N
N
Cl
N
R
H3CO
N
Cl
NaOMe
microwave irradiation 
8 - 10 mins.
DMF
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TABLE NO. 7a   :    COMPARISON OF CONVENTIONAL METHOD AND
MICROWAVE INDUCED SYNTHESIS OF 2-METHOXY-3-
CYANO-4-[1',N-PHENYL-3'-(2”,4”-DICHLOROPHENYL)
PYRAZOL-4'-YL]-6-ARYL PYRIDINES
CONCLUSION
We have demonstrated a rapid and general synthesis of acetyl pyrazolines and
methoxy pyridines using a microwave oven. Microwave technology is emerging as an
alternative energy source powerful enough to accomplish chemical transformation in
minutes, instead of hours. Consequently, reactions exhibit cleaner products and more
facile work-up procedures. For this reason, microwave irradiation is presently seeing an
exponential increase in acceptance as a technique for enhancing chemical synthesis.Moreover,
it can lead to improve isolated yields compared to conventional technology.
Comp.
  No.
R Thermal Microwave M. P.
 oCReaction
Period (hrs.)
Yield
  %
Reaction
Period (min.)
  7a C6H5- 10 75    9 78 160
7b 4-OCH3-C6H4- 10 67  10 69 280
7c 4-CH3-C6H4- 11 70    8 73 250
7d 4-Cl-C6H4- 10 58    9 60 196
7e 4-F-C6H4- 11 60    9 63 182
7f 4-Br-C6H4- 10 64    8 66 168
7g 4-OH-C6H4- 12 62  10 65 206
7h 2-OH-C6H4- 11 69    8 70 200
7i 4-NO2-C6H4- 10 60  10 62 176
7j 3-NO2-C6H4- 12 55  10 59 160
7k 2,4-(Cl)2-C6H3- 10 53    9 56 158
7l 4-NH2-C6H4- 11 61    8 63 188
Yield
  %
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